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1. INTRODUCTION 
Ischemic heart disease is the most lethal of 
cardiovascular diseases, and it is one of the leading 
causes of morbidity and mortality in humans worldwide, 
including European Union and Spain. The social impact 
of this disease is considerable, not only because of the 
mortality that it causes, but also because of its 
consequent morbidity, loss of quality of life, and high 
economic cost. This impact is largely due to its 
pathophysiological mechanism, namely, cardiomyocyte 
death.  
In ischemic heart disease, cardiomyocyte death 
almost always occurs as consequence of severe and 
prolonged myocardial ischemic events, which are mostly 
due to complications from atherosclerotic plaques in 
epicardial coronary arteries, causing an acute coronary 
syndrome. Coronary atherosclerosis develops in a 
clinically silent manner over years and only causes 
clinical symptoms when the arterial lumen is greatly 
narrowed, either due to atherosclerotic plaque growth or 
the development of intracoronary thrombosis induced by 
plaque complication, resulting in a loss of endothelial 
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RESUMEN: Esta Revisión se centra en la isquemia-
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al papel del óxido nítrico (NO) y endothelina-1 (ET-1) 
en la regulación de la circulación coronaria en 
condiciones normales y tras la isquemia-reperfusión. La 
ateromatosis coronaria suele estar causada por 
disfunción/daño endotelial, y lidera las causas de los 
síndromes coronarios agudos (p. e., infarto agudo de 
miocardio, IAM). El tratamiento más eficaz del IAM es 
la reperfusión del territorio de miocardio isquémico, 
pero este procedimiento también causa lesión del 
miocardio (lesión por reperfusión), cuya fisiopatología y 
tratamiento siguen siendo inciertos. La interacción entre 
el NO y ET-1 es relevante en la regulación de la 
circulación coronaria, y en condiciones normales 
predomina el NO sobre la ET-1. La circulación 
coronaria desempeña un papel crucial en la isquemia-
reperfusión puesto que ella es la causa y víctima de las 
consecuencias de esta situación. La isquemia-
reperfusión daña no solo el miocardio, sino también el 
lecho vascular coronario, aumenta los niveles 
plasmáticos de ET-1, induce el predominio de la ET-1 
sobre el NO, aumenta la respuesta coronaria alaET-1 y 
altera el papel de sus receptores en esta respuesta. Todo 
ello podría contribuir a la disfunción de la circulación 
coronaria y el fenómeno de no-reflujo y, como 
consecuencia, a la lesión por reperfusión. Así, la ET-1 
podría ocupar un papel destacado en la fisiopatología de 
la lesión por reperfusión, y el uso de antagonistas de los 
receptores ETA/ETB podría proteger al corazón frente a 
la lesiones por reperfusión.  
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continuity due to erosion, fissure, or endothelial rupture. 
Endothelial dysfunction and damage is a main factor for 
the formation of atheromatous plaques and development 
of coronary artery disease. Many clinical trials have 
suggested that lifestyle and pharmacologic interventions 
are effective in attenuating atherosclerotic disease 
progression and events development in coronary 
vasculature. Thus, preventing the appearance of 
atherosclerosis coronary plaques or their progression 
should be the first line of action against the disease.  
The atheromatous plaques, by producing severe 
stenosis and/or thrombosis of a coronary artery, may 
induce a pronounced reduction (>80%) of coronary blood 
supply in the distal territory of myocardium supplied by 
the artery affected, thus causing acute myocardial 
infarction (AMI). This entity frequently occurs in persons 
>45 years old, of which  ̴1/3 die within 28 days after 
beginning clinical symptoms. Studies of sex differences 
in long-term mortality after AMI have reported mixed 
results. Main determinants in evolution of patients with 
AMI are individual factors (e. g., age of patient), size of 
infarct, and time elapses between symptoms felt by 
patient and instauration of an effective treatment. The 
treatment should be directed to salvage the maximum 
amount possible of myocardium, by applying the 
adequate treatment as early as possible. Ischemic 
myocardial injury may also occur in clinical conditions 
such as heart transplantation, cardiac bypass, and 
coronary stenting after acute myocardial infarction (for 
details, see References 1-5).  
The incidence and fatality rates of an AMI are going 
down in developed countries as a result of better 
prevention and treatment. Basic and clinical researchers 
agree that the most effective treatment of AMI is timely 
(early) reperfusion by opening the stenosed/thrombosed 
coronary artery, thus restoring the blood flow to the 
ischemic myocardial territory. Timely restoration of 
blood flow to the ischemic zone of the myocardium 
limits infarct size and reduces mortality, and this 
reperfusion can be performed in patients, either by using 
thrombolytic agents (6) or percutaneous coronary 
angioplasty (7), and both of these procedures were 
initiated around 1975 (8). AMI is a dynamic process that 
frequently reaches the total extension of myocardium 
necrotized within 6h after initiating the artery occlusion. 
Myocardial reperfusion intents to stop expansion of 
myocardial damage, and this procedure represents a 
major step in treatment of patients with AMI. 
Reperfusion therapy is one of the most successful 
therapies of modern medicine. Today, primary 
percutaneous coronary angioplasty is the preferred 
strategy if the procedure can be performed by an 
experienced team within 90–120 min after the patient 
first presents (8). It is preferred because it can confer 
more rapid and complete revascularization, induces 
revascularization in a larger number of infarct-related 
coronary arteries and is associated with fewer bleeding 
complications. However, because access to invasive 
facilities is limited, thrombolytic therapy is still 
employed in many centers worldwide (8). In advanced 
countries, patients are now receiving the benefits of 
reperfusion therapy, and reducing time between 
symptoms onset and reperfusion therapy, is at present 
one of the main goals in the management of patients with 
AMI (9).  
Also, basic and clinical researchers agree that not all 
it is favorable with myocardial reperfusion, and as 
Braunwald and Kloner written at 1985, myocardial 
reperfusion is “a double edge sword” (10). Whereas it is 
very difficult to study the pathogenesis of human 
coronary syndromes such as AMI, experimental models 
have provided good reproducible means to explore 
different aspects of the events that occur after myocardial 
ischemia-reperfusion. Around the 1960s, R. B. Jennings 
and cols. brightly demonstrated in laboratory animals the 
consequences of a temporary occlusion of a coronary 
artery, as well as those of reperfusion by releasing this 
coronary occlusion (11, 12). They observed that 
reperfusion may also damage myocardium exposed to 
ischemia, and this damage is added to myocardial 
damage caused by ischemia itself, and it known as 
reperfusion injury (13). This phenomenon has been also 
described in the clinical setting (10).  
The coronary circulation plays a crucial role in the 
development of the effects of ischemia-reperfusion on the 
heart tissue. Indeed, the coronary circulation is the cause 
of the consequences of interruption of blood supply to 
cardiac tissue, as coronary artery disease is culprit of this 
interruption, and also it is victim of these consequences 
of blood flow deprivation as ischemia-reperfusion 
damages not only cardiomyocytes but also coronary 
vasculature. Furthermore, the coronary circulation is also 
protagonist in the process of reperfusion aimed to reduce 
the consequences of ischemia-reperfusion. Therefore, the 
coronary circulation should be considered with attention 
as it could play a central role in path physiology of 
myocardial ischemia-reperfusion and reperfusion injury, 
and also should be considered as a target of therapeutical 
strategies for cardioprotection (14). However, spite of 
relevance of the coronary circulation in ischemia-
reperfusion and reperfusion injury, this vasculature has 
received little attention in literature about this issue (14). 
The present Review focus on myocardial ischemia-
reperfusion, paying particular attention to the coronary 
circulation and to role of nitric oxide and endotheli-1 in 
the regulation of this vascular bed under normal 
conditions and after ischemia-reperfusion. Also, it will be 
considered therapeutical strategies for ischemia-
reperfusion injury, with greater mention to antagonists 
for endothelin receptors.  
2. THE CORONARY CIRCULATION 
2.1. General considerations 
Over the past several decades, the major factors 
determining myocardial perfusion have been elucidated, 
and this knowledge has been incorporated in the 
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management of patients with ischemic heart disease. The 
basic understanding of the flow mechanics of coronary 
stenoses have been also translated to the cardiac 
catherization laboratory where measurements of coronary 
pressure distal to a stenosis and coronary blood flow are 
routinely obtained (15, 16).  
The coronary circulation provides oxygen and 
nutrients to heart tissue, and the myocardium is very 
sensitive to oxygen deprivation. Coronary blood flow is 
determined, essentially, by aortic pressure, myocardial 
metabolism, neural factors, circulating vasoactive 
substances, and endothelial factors (1, 17, 18). 
Myocardial function is closely coupled to coronary blood 
flow and oxygen delivery, thus balance between oxygen 
supply and myocardial demand is a critical determinant 
of the normal heart function (1, 17-19). Figure 1shows a 
schematic representation of different aspects of the 
human coronary circulation.  
 
 
Figure 1. Schematic representation of the human coronary circulation: A) Drawing of the coronary circulation; LCA=left coronary artery; 
RCA=right coronary artery; LAD (AIA) =left anterior descending coronary artery; LCx=left circumflex coronary artery. B) Drawing of 
epicardial and intramural arteries; in the normal hearts, each area of myocardium is usually supplied by a single coronary artery and it 
does not have functional collaterals; and C) Drawing showing the different segments of coronary vascular system.  
In the human heart, the blood supply to the 
myocardium is provided by the two main coronary 
arteries that arise from the aorta: the left coronary artery 
and the right coronary artery; the left coronary artery 
branches to the left anterior descending and circumflex 
coronary arteries (Figure 1A). The left and the right 
coronary arteries are epicardial arteries (1-3 mm in 
diameter), they divide on the surface of the heart in a 
base to apex direction, and they are considered conduit 
arteries. These arteries send tributaries (400-1, 500 µm in 
diameter) which penetrate transmurally through the 
myocardial wall from the outer epicardium to the inner 
subendocardium (Figure 1B). After penetrating the 
myocardium, they branch to small arteries and arterioles 
(75-200 µm in external diameter) which are the primary 
sights of coronary vascular resistance. From the 
arterioles, a dense network of capillaries arises, running 
parallel with the cardiomyocytes ( ̴ 3, 500 
capillaries/mm2), with a gradient of vascularity favoring 
the endocardium; ratio of capillaries to cardiomyocytes 
is  ̴1:1. In addition, coronary mycrocirculation includes 
capillaries and postcapillary venules (Figure 1C). The 
coronary venous system is largely a mirror image of the 
coronary arterial system.  
Under normal conditions, there is not measurable 
pressure drop in the epicardial arteries, indicating 
negligible conduit resistance. When a significant 
epicardial artery narrowing is present (>50% diameter 
reduction), the fixed conduit artery resistance begins to 
contribute significantly to total coronary vascular 
resistance and, when these arteries are severely narrowed 
(>80% diameter reduction), it may reduce resting blood 
flow. The major component of coronary vascular 
resistance under normal conditions mainly arises from 
small arteries and arterioles, consequently called 
resistance vessels. This resistance is dynamic and 
distributed throughout the myocardium across a broad 
range of vessel sizes (50-400 µm in diameter). Because 
the diameter of these vessels, and hence their resistance 
can be changed by passive and active mechanisms, they 
play a pivotal role in the regulation of coronary blood 
flow. There is normally little resistance contributed by 
capillaries and coronary venules, and their resistance 
remains fairly constant during changes in vasomotor tone 
(16-18).  
Under resting conditions, a vasomotor tone exists to 
match oxygen delivery to metabolic need, and when 
elevated metabolic demand occurs, coronary blood flow 
can increase 5-fold primarily through arteriolar 
vasodilatation. This vasodilator reserve can also be 
utilized to maintain blood flow when perfusion pressure 
changes (16-18). When a 50% stenosis is present in a 
coronary conduit artery, this stenosis has little effect on 
blood flow due to autoregulatory reductions in arteriolar 
resistance (1, 16-18). However, during exercise or higher 
stenosis (~80%), blood flow may be compromised when 
arteriolar dilation is exhausted. Thus, conduit and 
resistance vessels work in harmony to defend myocardial 
perfusion. The inability of the microcirculation to 
compensate for changes in metabolism and perfusion 
pressure is one reason that examination of coronary 
arteriolar function is so important. There are a series of 
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collateral blood vessels that interconnects arteries, and 
under normal conditions these blood vessels have not 
functional connexions, but under some pathological 
conditions (e. g., arterial stenosis-obstruction) may 
provide functional salvage pathways of potentially 
ischemic areas of the myocardium (1, 16-18).  
After ischemia-reperfusion, the coronary circulation 
deserves attention because of it is damaged in different 
degree and it is a prime determinant of myocardial 
ischemia-reperfusion injury: it determines the area at risk, 
the duration of myocardial ischemia, the residual blood 
flow through collaterals, the microvascular obstruction 
and the restoration of coronary blood flow during 
reperfusion. Also, the coronary circulation is the site of 
cardioprotective interventions with intermittent coronary 
occlusion/reperfusion. Inadequate consideration for the 
coronary circulation might easily diminish the magnitude 
of differences in infarct size between the possibly 
protected group and the control group (14).  
2.2. The endothelium 
The artery wall has three layers, which are termed, 
from outer to inside, adventitia, media and intima. The 
intima is covered by the endothelium, which is a single 
layer of cells lining the inside of vascular wall. Before 
1980, the endothelium was merely considered as an 
anticoagulant sheet of cellophane, and at present it is 
accepted that the endothelium plays a crucial role in 
homeostasis of cardiovascular system. The healthy 
endothelium is able to produce a range of substances that 
regulate vascular tone, cellular adhesion, 
thromboresistance, smooth muscle cell proliferation, and 
vessel wall inflammation (19, 20).  
In 2009 P. M. Vanhoutte wrote: “First, there was 
Robert Furchgott. He simply and brilliantly demonstrated 
that endothelial cells play a pivotal role in relaxations 
evoked by acetylcholine in isolated arteries, and do so by 
activating muscarinic receptors of these cells” (21). In the 
late 1970s and early 1980s two cornerstone observations 
were made: the first, by Furchgott and Zawadzki, was the 
discovery of the "obligatory role of the endothelium in 
vasorelaxation by acetylcholine" (22), and the second, by 
Hickey and col., was the first description and 
characterization of a vasoconstrictor polypeptide 
produced by endothelial cells in culture (23). From the 
seminal observation by Furchgott and Zawadzki in 1980 
(22), an exponential number of studies have been 
performed by many researchers, in many laboratories 
through worldwide, and using different vascular beds and 
different experimental preparations (isolated blood 
vessels, isolated organs, anesthetized and unanesthetized 
animals). The intense laboratory and clinical research 
have let us to know that the endothelium can produce and 
release vasodilator and vasoconstrictor substances, as 
well as to know some pathways that regulate endothelial-
vascular smooth muscle communication (19). The 
reading of an interesting and nice article about the history 
of this issue, related by R. F. Furchgott, is recommended 
(24).  
The endothelium constitutes a large organ, and it is 
formed by approximately 1013 cells, which represents ̴1, 
5% of the total body mass (25). The endothelium derives 
from mesoderm, and in most of vascular beds it forms a 
continuous and non fenestrated layer that covers the 
internal surface of the blood vessel wall. When it is 
damaged, for instance after atherosclerosis, can be 
replaced by regenerated endothelial cells that may not 
have the same properties as normal cells (26, 27). The 
endothelium can produce and release endothelium-
derived relaxing factors such as nitric oxide (NO), 
prostacyclin (PGI2), endothelial derived hyperpolarizing 
factor (EDHF), hydrogen peroxide, carbon monoxide, 
hydrogen sulphide, C-t natriuretic peptide, and others; of 
these factors the most relevant seem to be NO, PGI2 and 
EDHF. The endothelium also can produce and release 
endothelium-derived contracting factors such as 
endothelin peptides, angiotensin II, thromboxane A2; in 
some circumstances hydrogen peroxide and prostacyclin 
can produce vasodilatation or vasoconstriction (19, 25). 
Under normal conditions predominates the release of 
vasodilator substances, particularly NO and, in 
consequence, the normal endothelium is pro-vasodilator. 
However, under pathological conditions in which the 
endothelium is damaged (i. e., atherosclerosis) secretion 
of vasodilator substances are reduced, whereas the 
release of vasoconstrictor substances such as endothelin-
1 (ET-1) may be augmented, the endothelium being now 
pro-vasconstrictor (19, 25, 26) (Figure 2).  
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Figure 2. Schematic representation of the relation of the endothelial release of relaxing and contracting factors in healthy, normal arteries 
(left), and unhealthy, diseased arteries (right).  
Early changes in endothelial function are indicators of 
future cardiovascular morbidity and mortality. 
Endothelial cell dysfunction related with aging in healthy 
persons is linked to telomere shortening, but it could be 
accelerated by risk factors, such as atherosclerosis, 
arterial hypertension, smoking, diabetes mellitus, obesity, 
and mechanical stress of a high heart rate (26-30). Such 
insults accelerate a proatherogenic phenotype (30-32). 
The statement “You are only as old as your 
endothelium”, attributed to Dr. Rudolf Altschul (1901-
1963), may be right.  
Our understanding of the role of the endothelium in 
the coronary vasculature under normal and pathological 
conditions is very notable (1, 15-18, 20, 30, 31). Due to 
its hemodynamic characteristics, the coronary vasculature 
may be the prime site for endothelial dysfunction (18) 
and displays an unusual gene pattern compared with 
other blood vessels, with lower endothelial NO synthase 
(eNOS) and higher of ET-1 mRNA expression (32). This 
pattern predisposes coronary vasculature to endothelial 
dysfunction and atherosclerosis, and coronary arteries are 
a main target for the aging and effects of cardiovascular 
risk factors. Summarizing, the coronary vasculature is 
prone to predominate the effects of ET-1 over those of 
NO with aging, cardiovascular risk factors and some 
pathological situations.  
The first demonstration of endothelial dysfunction in 
atherosclerotic coronary arteries using intracoronary 
infusion of acetylcholine (Ach) and quantitative coronary 
angiography dates back to 1986 (33). This observation 
drew attention to the functional manifestations of 
atherosclerosis such as exaggerated vasoconstriction as a 
consequence of poorly functioning endothelium. Later, 
less invasive techniques were developed using mainly the 
forearm circulation as a surrogate for coronary arteries 
(30, 31, 34, 35).  
Atherosclerosis, the main cause of acute coronary 
syndrome, courses with endothelial dysfunction, and this 
dysfunction could play a relevant role in pathophysiology 
of myocardial ischemia-reperfusion. And also, 
myocardial ischemia-reperfusion by itself is a clinical 
and laboratory entity that may be accompanied by 
damage and dysfunction of coronary vasculature, 
particularly of the endothelium (see below). These ideas 
support the interest for investigate the functional aspects 
of the coronary circulation after myocardial ischemia-
reperfusion in order to know the pathophysiology of this 
condition, as well as to design therapeutic strategies to 
ameliorate the consequences of acute myocardial 
infarction and reperfusion injury, and thus the outcome of 
patients with these abnormalities.  
In the past decade, many studies have suggested that 
the noninvasive assessment of endothelial function may 
provide useful information for individual patient risk, 
progress, and guidance of therapy.  
2.3. Nitric oxide (NO)  
In mammals, including humans, nitric oxide (nitrogen 
oxide or nitrogen monoxide) is an important cellular 
signaling molecule involved in many physiological and 
pathological processes (for revision of this issue, see 
reference 36).  
NO is a gas that has not colour, odour, or taste, with 
low solubility in water at room temperature and at 
atmospheric pressure. In blood, it reacts predominantly 
with molecules that have orbitals with unpaired electrons, 
which are typically other free radicals (superoxide ion, 
hydroxyl ion) or transition metals like heme iron 
(hemoglobin, myoglobin, cytochromes). Reactions of NO 
differ between in vitro and in vivo systems. In in vitro 
systems, the main degradation product of NO is NO2- 
(nitrite), while in vivo the main product is NO3- (nitrate) 
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as a consequence of the reaction of NO with hemoglobin.  
This molecule can become highly toxic to tissues 
during some pathological conditions (e. g., ischemia and 
reperfusion). NO by reacting with anion superoxide 
(O2•−) forms peroxynitrite (ONOO−), which is a 
powerful oxidant and seems to be a determinant in the 
contrasting roles of NO in physiology and pathology. 
Peroxynitrite interacts with lipids, DNA, and proteins via 
direct oxidative reactions or via indirect, radical-
mediated mechanisms, which may commit cells to 
necrosis or apoptosis. In vivo, peroxynitrite generation 
represents a crucial pathogenic mechanism in conditions 
such as stroke, myocardial infarction, chronic heart 
failure, diabetes mellitus, circulatory shock, chronic 
inflammatory diseases, cancer, and neurodegenerative 
disorders.  
The regulation and synthesis of NO by mammalian 
cells has been the focus of many reviews (36, 37), as 
have been many of its physiological and pathological 
actions (38, 39). For a century, nitrovasodilators had been 
used clinically without understanding their mechanism of 
action. Alfred Nobel lamented the irony that he was 
taking nitroglycerin to treat angina after making his 
fortune developing dynamite.  
As several studies suggested that the characteristics of 
NO and EDRF are similar, R. Furchgott proposed that the 
EDRF produced by endothelium is NO (40, 41), and 
Ignarro provided additional evidence supporting the 
identification (42, 43). Moncada et al. were able to 
directly measure NO produced in vivo (44).  
The synthesis of NO from arginine is catalyzed by 
three forms of NO synthase (endothelial NO (eNO) 
synthase, neuronal NO (nNO) synthase, and inducible 
NO (iNO) synthase). The brain proved to be a rich source 
of NO synthesis and allowed the first NO synthase to be 
cloned and purified (45, 46). It is called nNOS or NOS1 
as it was the first synthase to be cloned. The NOS1 gene 
has the most complex genomic organization in humans 
with multiple splice variants being produced (47). The 
second NO synthase to be cloned was isolated from 
macrophages and is known as NOS2 or iNOS (inducible 
NOS) because it is readily induced in many tissues by 
proinflammatory cytokines. Because NOS2 can be 
strongly induced by proinflammatory stimuli, it induces 
often a high production of NO. The first source of NO 
identified was the endothelium, but eNO synthase was 
the last to be cloned and is known as eNOS or NOS3. 
NOS3 binds to plasma membranes and is typically 
associated with caveolin (48). It is strongly activated by 
the entry of calcium through membrane-bound receptors 
and is also regulated by phosphorylation (49). NOS3 is 
also found in neurons and other tissues in addition to 
endothelium (36). NO is also produced by myocardium, 
and it is involved in several aspects of physiological 
myocardial function (e. g., excitation-contraction 
coupling; myocardial relaxation; diastolic function; the 
Frank-Starling response; heart rate; β-adrenergic 
inotropic response; and myocardial energetics and 
substrate metabolism) (50, 51). Figure 3 summarizes the 
source and the beneficial effects of NO on blood vessels.  
 
 
Figure 3. Summary of the source and beneficial effects of NO (nitric oxide) in blood vessels.  
NO is an indicator of vascular endothelial function, 
and measurements performed in control (normal) humans 
provide that eNO synthase activity is 7-8 U/mL, and NO 
levels (expressed as NO3) are approximately 60 µmol/L. 
NO is released from the endothelium under normal 
conditions as the endothelium acts as a sensor that is 
stimulated by flow changes, stretch, a variety of 
circulating vasoactive substances, and inflammatory 
mediators. The release of NO can increase or decrease in 
patients under certain pathological conditions. The 
release of NO can be pharmacologically inhibited by 
using analogues of arginine such as Nw-Nitro-L-arginine 
methyl ester (L-NAME) and L NG-monomethyl-L-
arginine (L-NMA). These inhibitors have been used in 
laboratory experiments to explore contribution of NO in 
the regulation of vascular tone (52, 53).  
In general, NO acts stimulating intracellular 
guanylate cyclase, and this enzyme converts GTP in 
cGMP. There are two types of guanylate cyclase: one is 
an integral membrane protein with an extracellular 
Godofredo Diéguez Castrillo 
 
@Real Academia Nacional de Farmacia. Spain 20 
domain and an intracellular catalytic domain that 
synthetizes cGMP; the other is cytoplasmatic (soluble 
guanylate ciclase) and is the isoform that is the form 
activated by NO. In the nervous system, NO acts directly 
to open cyclic nucleotid-gated channels, and it activates 
the cGMP-dependent protein kinase (36). NO, after it is 
released by the vascular endothelium, is free to diffuse 
into adjacent smooth muscle cells of the vascular wall, 
and in these cells directly activates soluble guanylate 
cyclase. This enzyme induces the formation of cGMP, 
which in turn activates cGMP-specific protein kinases 
that affect ion channels, calcium hemeostasis, or 
phosphatases, or all of these, causing relaxation of 
vascular smooth muscle (36).  
As loss of NO bioavailability indicates a broadly 
dysfunctional phenotype across many properties of the 
endothelium, the assessment of its vasodilator properties 
resulting from NO and other molecules may provide 
information on the integrity and function of the 
endothelium. Interestingly, most, if not all, 
cardiovascular risk factors are associated with endothelial 
dysfunction and risk factor modification leads to 
improvement in vascular function (37, 54). Over the past 
35 years, many methodological approaches have been 
developed to measure the (patho) physiological function 
of the endothelium in humans (55), but evaluation of 
endothelial function as a clinical tool in daily practice is 
not established yet.  
From the beginning, endothelial function has been 
regarded as an important factor in the regulation of the 
coronary circulation and it may be of pathophysiological 
significance in several coronary diseases (1, 15-18). 
Endothelium-dependent vasodilatation has been found in 
coronary vessels from dogs (56) and man (57). Then it 
was reported that human coronary vessels in vitro release 
NO (58), that NO plays a significant role in modulating 
basal vasomotion and endothelial-dependent dilatation in 
the coronary circulation of dogs (59), and that the 
coronary vascular relaxation by NO, as well as by 
nitroprusside is associated with an increase in cGMP 
(60).  
In our laboratory we have carried out a series of 
experiments to examine the functional role of NO in the 
coronary circulation under normal conditions, and they 
were performed using three laboratory models 
(anesthetized goats, isolated, perfused hearts from rats, 
and isolated coronary arteries from pigs). In these three 
models we found that in the coronary circulation, NO 
may be released under basal conditions, it produces a 
basal vasodilator tone, it mediates the vasodilation in 
response to Ach, and it reduces the response to 
vasoconstrictors such as ET-1. In anesthetized goats, L-
NAME, injected by i. v. route, decreased resting coronary 
blood flow and increased systemic arterial pressure. 
These hemodynamic effects of L-NAME were partially 
reversed by L-arginine injected intravenously. We also 
found that during the effects of L-NAME, the coronary 
vasodilatation to Ach was attenuated, to sodium 
nitroprusside was increased, and to diazoxide was 
unaffected. Graded coronary hyperemic responses after 5, 
10 or 20 s of coronary occlusion were increased during 
treatment with L-NAME. These results suggest: a) 
endogenous NO is involved in regulation of coronary 
circulation by producing a basal vasodilator tone; b) Ach-
induced coronary vasodilatation is mediated, in part, by 
NO; and c) inhibition of basal endogenous NO 
production induces supersensitivity of coronary vessels 
to nitrovasodilators and enhances hyperemic responses 
after short periods of ischemia of the myocardium (61). 
This agrees with observations by others in the coronary 
circulation, and supports the idea that a vasodilator tone 
mediated by NO is present in the coronary circulation. 
The effects of sodium nitroprusside were increased 
during the action of L-NAME. Sodium nitroprusside has 
been used as a donor of exogenous NO and produces 
vasodilatation in a similar way to NO (62). Enhanced 
vasorelaxant responses to sodium nitroprusside and other 
nitrous compounds have been found in the absence of a 
functional endothelium or in the presence of L-arginine 
analogues, and this has been related to an increased 
sensitivity of guanylate cyclase in vascular musculature 
to exogenous NO when production of endogenous NO is 
reduced (63, 64). Therefore, it appears that the removal 
of endogenous NO in the vasculature could lead to 
increases in sensitivity to vasodilators that act by 
stimulating soluble guanylate cyclase. Reactive 
hyperemia after short ischemias of the myocardium is 
known to occur in the coronary circulation, and 
metabolic and hemodynamic factors that contribute to the 
hyperemic response have been explored. However, little 
is known about the role of the endothelium in the 
coronary hyperemic response (56, 59, 65).  
Also in anesthetized goats, when L-NAME was 
intracoronarily injected, it reduced resting coronary blood 
flow without changing systemic arterial pressure. These 
effects of L-NAME were also partially reversed by L-
arginine. Isoproterenol, adenosine and Ach, injected 
intracoronarily, increased coronary blood flow, and after 
treatment with L-NAME the increases in coronary blood 
flow induced by isoproterenol and Ach were reduced, 
whereas those induced by adenosine were increased 
further. Therefore, it is confirmed that in the coronary 
circulation NO produces a basal vasodilator tone under 
normal conditions, and it is suggested that NO may be an 
intermediate in the coronary vasodilatation in response to 
beta-adrenoceptor stimulation and Ach, and that the 
vasodilatation due to adenosine is potentiated during 
reduction of endogenous NO production (66) (See Figure 
4).  
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Figure 4. Actual recordings of coronary blood flow (CBF, electromagnetically measured), systemic arterial pressure (SAP) and heart rate 
(HR) obtained in anesthetized goats: A) during i. v. administration of the inhibitor of NO synthesis L-NAME; B) during intracoronary (i. 
c) administration of this substance; and C) showing the effects of intracoronary injections of acetylcholine (Ach) on coronary blood flow 
before (control) and after L-NAME injected by i. v. route; D) Summary of the effects of intracoronary injections of acetylcholine (Ach) 
and sodium nitroprusiate (SNP) on coronary blood flow in anesthetized goats under control conditions and after i. v. administration of L-
NAME.  
2.4. Endothelin-1 (ET-1)  
Endothelin-1 is a member of the group of endothelins, 
which are a family of 21- amino-acid peptides, and they 
include endothelin-1 (ET-1), endothelin-2 (ET-2) and 
endothelin-3 (ET-3); they share structure homology with 
the snake venom sarafotoxin b and c (S6b and S6c) (67, 
68).  
The presence of an endothelium-derived constricting 
factor (EDCF) was perceived 1 year after the revelation 
of the endothelium-derived relaxant properties of the 
endothelium (69). However, it was 8 years later that 
Yanisagawa et al. identified an EDCF, ET-1 (70, 71). 
Two years later, two types of receptors for ET-1 were 
identified (72, 73), and shortly after the discovery of 
ETA y ETB receptors, M. Clozel et al. presented in 1993 
the first orally active ET-1 receptor antagonist, Ro 46-
2005 (74).  
ET-1 is one of the most potent endogenous 
vasoconstrictor identified so far (67, 68). This peptide 
induces a long-lasting contraction of arteries of different 
regions, including coronary arteries, and it contributes to 
cardiovascular homeostasis through several pathways 
that impact on the regulation of basal vascular tone (75). 
It is released continuously, mostly from endothelial cells, 
by a constitutive and regulated pathway (76), and acts 
primarily as a paracrine regulator of vascular tone (75-
78). In addition to endothelial cells, ET-1 is also 
produced by vascular smooth muscle cells, 
cardiomyocytes, leukocytes, macrophages, some types of 
neurons, and other types of cells (67, 77, 78). ET-1, at 
elevated concentrations, also induces inflammatory 
effects and promotes proliferation of vascular smooth 
muscle cells (67, 68, 79).  
ET-1, ET-2 and ET-3 are encoded by different genes, 
on chromosomes 6, 1 and 2, respectively (67, 68). In 
endothelial cells, the product of the ET-1 gene is 
processed from a large precursor peptide of 
approximately 200 amino acid residues (preproET-1) to 
39-amino-acid prohormone (big ET-1), which has about 
1% of the activity of ET-1. This prohormone is then 
cleaved to form ET-1 by the action of two endothelin-
converting enzymes (ECE-1 and ECE-2) (67, 68). Small 
amounts of big endothelin and ET-1 are secreted into 
circulating blood and into interstitial space of the blood 
vessel wall (67, 68). In normal human adults, plasma 
levels of ET-1 are relatively low (0. 7-6 pg/mL (75, 76). 
ET-1 is cleared from the circulating plasma, and the 
majority is retained by the lungs and cleared from the 
circulation by binding to endothelin ETB receptors (67, 
68). ET-1 is not stored in secretory granules, and factors 
that active its secretion may be angiotensin II, 
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catecholamines, grow factors, hypoxia, insulin, 
lipoproteins, thrombin; contrarily, factors that inhibit its 
secretion are NO, atrial natriuretic peptide, prostaglandin 
E, PGI2 (67, 68). The concentration of ET-1 in plasma 
may increase in some cardiovascular diseases such as 
myocardial infarction, ischemia-reperfusion syndrome, 
and heart failure (78, 80).  
The biological effects, including vascular effects of 
ET-1 may be mediated by two types of receptors, i. e., 
endothelin ETA and endothelin ETB; endothelin ETB 
receptors are subdivided in ETB1 and ETB2. ETA 
receptors are located in smooth muscle cells and coupled 
to protein G, and its activation leads to increment of 
cytoplasmic Ca, and then vasoconstriction (67, 68). The 
debate in literature exists whether or not ETA and ETB 
receptors should be blocked to provide most clinical 
benefit (67, 76, 81); this feature may be of clinical 
relevance, for example in treatment of myocardial 
reperfusion injury. The ETA receptor has been 
considered as the bad one, while the ETB receptor has 
been considered as the good one; this distinction is based 
on the role of ETB1 in the clearance of circulating ET-1 
and on the finding that activation of this particular 
receptor produces vasodilation by releasing NO. Whereas 
the role of ETA receptors in vascular function is 
relatively well known, the role of ETB receptors is less 
known. Both ETB1 and ETB2 receptors are also a G-
protein coupled receptor and have been identified in 
numerous types of blood vessels, including coronary 
arteries. ETB1 receptors, situated in the endothelium, 
mediate the release of relaxant factors (NO, PGI2, 
EDHF), and they may play a role in ET-1 clearance, and 
ETB2receptors, situated in vascular smooth muscle cells, 
mediate the increase of concentrations of intracellular Ca, 
protein kinase C, mitogen-activated protein kinase and 
other pathways of vascular smooth cells contraction and 
cell growth (67, 68).  
In spite of many data demonstrating that ET-1 is a 
powerful vasoconstrictor, there are also data suggesting 
that under healthy conditions, ET-1 can also induce in 
vivo vasodilatation. In any case, the overall effects of 
ET-1 on vascular tone in vivo maybe the result of the 
balance between the effects mediated by ETA and ETB2 
receptors located in smooth muscle cells, and the effects 
mediated by ETB1 receptors located in endothelial cells 
(82, 83), and this could dependent on whether blood 
vessels are healthy or unhealthy. Aging and pathological 
conditions (e. g., cardiovascular diseases) facilitate the 
predominance of the vasoconstrictor effects of ET-1.  
Another cardiovascular function that may be of 
relevance is that ET-1 may be a regulator of cardiac 
physiology and pathology. Produced locally within the 
myocardium in response to diverse mechanical and 
neurohormonal stimuli, ET-1 seems to modulate cardiac 
contractility. During pathological cardiovascular 
conditions such as ischemia, left ventricular hypertrophy 
and heart failure, myocyte expression and activity of the 
ET-1 system is enhanced, allowing the peptide to both 
initiate and maintain maladaptive cellular responses. 
Both the myocardial acute and chronic effects of ET-1 
are dependent on the activation of intracellular signaling 
pathways, regulated by the inositol-trisphosphate and 
diacylglycerol produced upon activation of the ETA 
receptor. Subsequent stimulation of protein kinases C and 
D, calmodulin-dependent kinase II, calcineurin, and 
mitogen-activated protein kinases modifies the systolic 
calcium transient, myofibril function and the activity of 
transcription factors that coordinate cellular remodeling 
(67, 68).  
Due to its potent effect on the coronary circulation, 
the interest for the role of ET-1 in the physiology and 
pathology of this particular vasculature increased rapidly. 
In the first publication where ET-1 was identified, also it 
was indicated that this peptide provokes a pronounced 
constriction of isolated coronary arteries (70, 71), and 
since this observation most of data show that ET-1 
produces pronounced coronary vasoconstriction in vivo 
(84, 85) and in vitro (70, 71, 86, 87).  
In our laboratory we found that ET-1 evokes marked 
coronary vasoconstriction in vivo and in vitro. In 
anesthetized goats, i. v. injections of ET-1 increased 
systemic arterial pressure, did not change resting blood 
flow in the left anterior descending or left circumflex 
coronary (LCx) arteries, and in the middle cerebral artery 
(MCA) arteries, but it increased coronary and cerebral 
vascular resistance, and this increment was higher in the 
coronary circulation than in the cerebral circulation. In 
other group of anesthetized goats, intra-arterial injections 
of ET-1 decreased the LCx flow more than MCA flow. In 
isolated segments from large coronary and cerebral 
arteries from goats, ET-1 caused contraction, and the 
concentration causing 50% of the maximal effect and the 
maximal contraction were higher in coronary arteries 
than in cerebral arteries. The in vitro reactivity of these 
two types of arteries was unaffected by endothelium 
removal or by indomethacin. Therefore, ET-1 may 
produce coronary and cerebral vasoconstriction in vivo 
and in vitro, probably by acting directly on vascular 
musculature. The results from this study suggest that the 
sensitivity to this peptide is higher in isolated cerebral 
arteries than in isolated coronary arteries, but the 
reactivity in vivo could be higher in the coronary 
circulation than in the cerebral circulation (88). The 
coronary vasoconstrictor effect of ET-1 was also 
observed in isolated, perfused hearts from rats (89), and 
in isolated coronary arteries from pigs (90). Figure 5 
shows actual recordings of the coronary effects of ET-1 
in one anesthetized goat and in one isolated, perfused rat 
heart.  
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Figure 5. Actual recordings of the coronary effects of ET-1obtained in one anesthetized goat (left) and in one isolated, perfused rat heart 
(right); I. c. =intracoronary.  
There are studies suggesting that the coronary 
vasoconstriction by ET-1 is mediated by ETA receptors 
in humans (91), pigs (92) and rats (93), and that the role 
of ETB receptors is not clear, although it may be of less 
significance (91). Balwierczak (94) reports data 
suggesting that coronary response to ET-1 is mediated by 
both ETA and ETB receptors. With regard to the role of 
NO, it has been suggested that ET-1 can release NO in 
the coronary vasculature, and that this NO induces 
vasodilatation (92, 95) and counteracts the 
vasoconstriction produced by ET-1 (93). Regard to the 
role of prostanoids, the results reported are contradictory 
(93, 95). In our laboratory, we observed that ET-1, 
intracoronarily injected, produced marked reductions in 
coronary blood flow, and that these effects were 
diminished by BQ-123, specific antagonist for endothelin 
ETA receptors, but not during the infusion of BQ-788, 
specific antagonist for endothelin ETB receptors. IRL 
1620, specific agonist for endothelin ETB receptors, 
intracoronarily injected, slightly reduced basal coronary 
blood flow. The effects of IRL 1620 were not modified 
by BQ-123 or BQ-788. With L-NAME, the reductions of 
coronary blood flow by ET-1 were potentiated and those 
by IRL 1620 were not changed. Meclofenamate 
(cyclooxygenase inhibitor) modified neither the basal 
values of hemodynamic variables nor the coronary 
effects of ET-1 and IRL 1620. Therefore, ET-1 produces 
pronounced coronary vasoconstriction, which may be 
mediated by endothelin ETA receptors, with no 
participation of endothelin ETB receptors; NO, but not 
prostanoids, may inhibit ET-1-induced coronary 
vasoconstriction. Also, it is suggested that the coronary 
vasoconstriction by ET-1 may impair cardiac 
performance due to heart ischemia (96). From the studies 
with ET-1 and L-NAME in isolated, perfused hearts from 
rats (89) and in isolated coronary arteries from pigs (90) 
similar conclusions can be obtained about the modulatory 
role of NO in the coronary effects of ET-1 (see below 
Ischemia-reperfusion). Figure 6 shows an estimation of 
possible interaction between NO and ET-1 in the 
coronary circulation derived from the observed effects of 
inhibition of NO synthesis with L-NAME on the 
coronary response to ET-1 in anesthetized goats (96), 
isolated hearts from rats (89) and isolated coronary 
arteries from pigs (90).  
 
 
Figure 6. Summary of the effects of inhibition of NO synthesis with L-NAME on the action of ET-1 in the coronary circulation of 
anesthetized goats (A) and of isolated, perfused hearts from rats (B), as well as in isolated coronary arteries from pigs (C). The 
augmentation of the coronary response to ET-1 was qualitatively similar in the three experimental preparations.  
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ET-1 may also exert other vascular functions, as for 
example to modulate the response of coronary arteries to 
other types of vasoactive stimuli. The relaxation to 
isoproterenol, field electrical stimulation, Ach, and 
sodium nitroprusside was recorded in isolated coronary 
arteries from rats, in the absence and in the presence of 
ET-1. It was found that the treatment with ET-1 increased 
the relaxation to isoproterenol and did not modify the 
relaxation to electrical stimulation, Ach, or sodium 
nitroprusside The increased relaxation to isoproterenol in 
the presence of ET-1 was also present in the presence of 
the endothelin ETB antagonist BQ788 but disappeared in 
the presence of the endothelin ETA antagonist BQ123 or 
the blocker of protein kinase C chelerythrine. Thus, 
curiously, ET-1 may potentiate coronary beta-adrenergic 
vasodilatation, due at least in part to stimulation of 
endothelin ETA receptors and activation of protein 
kinase C (97).  
Arginine-vasopressin (AVP) is a hormone that may 
be of significance in the regulation of coronary 
circulation, particularly under certain pathological 
conditions such as myocardial infartion (see below 
Ischemia-reperfusion). In anesthetized goats we have 
found that under normal conditions, AVP produces 
coronary vasoconstriction and that this vasoconstriction 
may be mediated by vasopressin V1 receptors, without 
involvement of vasopressin V2 receptors; and it is 
probably modulated by NO, but not by prostanoids (98). 
These results in coronary vasculature of goats are in line 
with those obtained in coronary vasculature from rabbits 
(99). In one study performed in arteries taken from 7 
vascular beds of rabbits, we found that in isolated 
arteries, AVP induced contraction in central ear 
(cutaneous), basilar (pial), renal, coronary and saphenous 
(muscular) arteries, but had no effect in mesenteric and 
pulmonary arteries; the order of potency for the 
contraction to this peptide was: ear > basilar > renal > 
coronary > saphenous arteries. Treatment with L-NAME 
increased the contraction to AVP in ear (148% of 
control), basilar (150% of control), renal (304% of 
control), coronary (437% of control) and saphenous 
(235% of control) arteries. Removal of the endothelium 
increased the contraction to AVP in basilar (138% of 
control), renal (253% of control), coronary (637% of 
control) and saphenous (662% of control) arteries, but 
not in ear artery. Mesenteric and pulmonary arteries in 
the presence of L-NAME or after endothelium removal 
did not respond to AVP, as occurred in control 
conditions. The specific blockade of V1 vasopressin 
receptors was more potent than the blockade of both V1 
and V2 vasopressin receptors to block the contraction to 
AVP. In arteries precontracted with endothelin-1, 
vasopressin or desmopressin did not produce relaxation. 
Therefore, these results suggest: a) most arterial beds 
studied (5 of 7) exhibit contraction to AVP with different 
intensity; b) the vasoconstriction to this peptide is 
mediated mainly by stimulation of V1 vasopressin 
receptors, and c) endothelial NO may inhibit the 
vasoconstriction to this peptide, especially in coronary 
and renal vasculatures (99). From this study (99) it is 
apparent that NO plays a relevant role in modulating the 
vascular effects of AVP, and that this role is relatively 
more pronounced in coronary vasculature than in other 
vasculatures. In other study we compared the coronary 
effects of ET-1 and AVP in anesthetized goats, and the 
results suggest that ET-1 is more effective than AVP for 
producing coronary vasoconstriction (Figure 7), that NO 
may play a more relevant role for modulating the 
coronary vasoconstriction provoked by ET-1 than by 
AVP (Figure 7), and that cyclooxygenase products may 
not be involved in the coronary effects of these two 
peptides (100). From these results it can be estimated that 
after inhibition of NO synthesis with L-NAME, the 
increase in coronary vasoconstrictor effects produced by 
ET-1 is about two times higher than those induced by 
AVP (Figure7).  
 
Figure 7. Comparison of the coronary vasoconstrictor effects of ET-1and AVP (left), and of the relative role of NO in modulation of 
these effects (right). These studies were performed in anesthetized goats and both peptides were injected intracoronarily (i. c.).  
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2.5. Interaction between NO and ET-1 
The functional interaction between NO/ET-1 deserves 
attention for its implication in the regulation of vascular 
function under normal and some pathological conditions. 
The release of ET-1 is inhibited by NO from the 
endothelium (83, 101), which make NO and ET-1 
functionally closely interdependent, with a strong 
inhibitory effects of ET-1 on NO-mediated dilation, and 
vice versa (102-104). Endothelial dysfunction is 
associated with a decline in the contribution of NO in 
favor of greater influence of ET-1 on vascular function, 
and this phenomenon seems to be more evident in the 
coronary circulation under certain pathological 
conditions (80). This alteration in the balance between 
NO and ET-1 under certain conditions may be one of the 
aspects underly dysfunction of the coronary circulation 
with deleterious consequences for the myocardium (78, 
80).  
Alterations in the NO/ET-1axis can lead to disbalance 
in vascular endothelial function, resulting in pathological 
changes (105). With regard to this, it has been 
demonstrated that intracoronary infusion of BQ123 
resulted in beneficial effects on coronary diameter and 
coronary blood flow in patients with coronary artery 
disease (106). Other observations also support the idea 
that in patients with coronary artery disease, less NO is 
produced and more ET-1 would contribute to vascular 
tone (80), and this hypothesis was tested in patients with 
coronary artery disease where it was proved that ET-1, 
via endothelin ETA receptors, contributed to the 
reduction of endothelial dilatory response (107). Other 
study in patients with coronary artery disease shows that 
blockade of endothelin ETA receptors or blockade of 
both endothelin ETA and ETB receptors improved the 
endothelium-dependent dilation in coronary arteries 
(108). Data from other studies also suggest that when 
more severe is atherosclerosis in coronary arteries, more 
importance has ET-1 in the control of coronary artery 
tone, thus functional contribution of this peptide appears 
to rise with the severity of coronary artery disease (80).  
Other circumstance in which interaction between NO 
and ET-1 may be altered is during aging. This condition 
may be associated with alterations in the cardiovascular 
system, and with increased ET-1 plasma levels. From a 
study performed in hearts from young (3 months old), 
aged (24 months old) and aged rats after 3 months of 
caloric restriction, it is suggested that aging is 
accompanied by alterations in myocardial and coronary 
responses to ET-1, that may be related to changes in 
expression of NO synthases and/or endothelin receptor 
subtypes, with some of these changes being prevented by 
caloric restriction (109).  
The relation between NO and ET-1 may be also 
altered during hypotension. In anesthetized goats, during 
acute hypotension induced by constriction of the caudal 
vena cava, it was found that: 1) under normotension, ET-
1 and AVP, intracoronarily injected, decreased coronary 
vascular consuctance (CVC) by up to 56% for ET-1 and 
40% for AVP; 2) under non-treated hypotension, the 
decreases in CVC byET-1 were augmented 
approximately 1. 5 fold, and those by AVP were not 
modified; 3) this increase in CVC by ET-1 was not 
affected by L-NAME and was reversed by 
meclofenamate, and 4) the coronary effects of AVP were 
not modified by any of these treatments. Therefore, acute 
hypotension increases the coronary vasoconstriction in 
response to ET-1 but not in response to AVP, and this 
increased response to ET-1 may be related to both 
inhibition of NO release and release of vasoconstrictor 
prostanoids (110).  
The data exposed above suggest that NO and ET-1 
play a relevant role in the regulation of the coronary 
circulation, and that a functional intereration between 
these two substances could be of relevance in the control 
coronary vacular tone. When it is compared the role of 
NO in the coronary effects of ET-1 and AVP, the data 
suggest that the interaction between NO and ET-1 is 
greater that the interaction between NOand AVP in the 
regulation of the coronary circulation (see Figure 7).  
Summarizing, the alteration in NO/ET-1 axis may 
play a relevant role on pathogenesis of coronary artery 
disease, and thisaxismay be a target for therapeutic 
interventions in some pathological conditions (e. g., 




Figure 8. A) Schematic representation of a transverse section of a normal artery showing the layers of the artery wall, the release of NO 
and ET-1 by endothelial cells, and chemical structure of these two substances. B) Schematic representation of changes in the relative role 
of NO and ET-1 in the regulation of vascular tone after aging, cardiovascular risk factors and some cardiovascular diseases (CVD).  
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3. ISCHEMIA AND REPERFUSION 
Sudden interruption of blood supply through a 
coronary artery can occur in patients as a result of the 
rupture or erosion of an atherosclerotic plaque situated in 
the wall of a coronary artery, with a superimposed 
thrombosis of this artery. Sudden interruption of blood 
supply through a coronary artery also can be reproduced 
in laboratory animals in which mechanical occlusion of a 
coronary artery can be induced. In both cases, coronary 
occlusion results in myocardial infarction if coronary 
perfusion is not restored within <40 min. Following a lag 
phase of fully reversible damage, myocardial infarction 
spreads depending on duration of coronary occlusion as a 
wave front phenomenon from the most central core of the 
affected coronary perfusion territory to its peripheral 
borders. The main determinants of the final amount of 
myocardium affected (size of the myocardial infarction) 
are the coronary circulation (area at risk), duration of 
coronary occlusion and presence of collateral blood flow. 
The area at risk is the anatomic perfusion territory of the 
coronary artery distal to the site of its occlusion, and this 
area determines myocardial infarct size, and infarct size 
is a principal determinant of prognosis of patients. The 
duration of coronary occlusion is determined both by the 
initial occlusive event and the restoration of coronary 
perfusion, and this restoration may be spontaneous or 
through a therapeutic intervention. In healthy and young 
experimental animals, the coronary circulation may be 
not compromised by atheromathosis and the onset and 
release of the mechanical coronary occlusion are clearly 
defined. In patients, however, the situation is very 
different and more complex, as coronary vasculature is 
usually deseased, and complete coronary occlusion may 
be preceded by intermittent changes in blood flow. In 
addition to the area at risk and the duration of coronary 
occlusion, residual blood flow through the coronary 
collateral circulation may be a significant determinant of 
infarct size. Studies in experimental animals have been 
performed in species with and without an innate coronary 
collateral circulation, and therefore the conditions differ. 
In humans, that have an innate coronary collateral 
circulation, the possibility of a recruitable collateral 
circulation may improve the outcome of patients with 
coronary artery disease (for details, see Reference 14). 
Questions that could be of interest about this particular 
issue are: damage of coronary vasculature and of 
cardiomyocytes develops in parallel during ischemia-
reperfusion? Damage of coronary vasculature and of 
cardiomyocytes influences each other during this 
condition? 
In relation to the effects of ischemia and reperfusion 
on the heart, there are recent excellent revisions (9, 13, 
14, 111-114), and these effects are summarized below.  
3.1. Effects of ischemia 
Coronary occlusion results in abrupt deprivation of 
oxygen supply to the myocardium, which induces 
ischemia and, it left uncorrected, death of myocytes by 
necrosis. Cessation of oxygen supply disrupts aerobic 
metabolism and oxidative phosphorylation with the 
consequent depletion of ATP and other energy 
compounds, and increased concentration of lactate and 
acidosis in cardiomyocytes. Depletion of energy 
compounds rapidly causes myocardial dysfunction and 
detrimental effects on biochemistry and metabolism of 
cardiomyocytes. These effects of oxygen deprivation, 
however, can be reversed if the duration of ischemia lasts 
<20 min. But if ischemia continues, irreversible injury 
develops, which is characterized by disruption of 
plasmatic, sarcolemmal and lisosomal membranes of the 
cardiomyocytes. This induces loss of osmotic balance, 
alteration of ions exchange through membranes and 
leakage of cellular metabolites into the extracellular 
space, with increased concentration and overload of 
calcium inside of cells and remaining closed the 
mitochondrial permeability transition pore. Damage of 
mitochondrial membranes reduces the ability of cells to 
produce ATP upon reperfusion, as well as the release of 
digestive enzymes, culminating in cell necrosis and 
apoptosis (13, 111-114).  
The consequences of ischemia depend on several 
factors, as for example the duration of the occlusion 
(115), whether this ischemia is partial or global, and the 
presence or not of functional collateral circulation (116). 
Shrader et al. observed a reduction of 65% in ATP after 
15 minutes ischemia (117), and Jones et al. in a murine 
model observed a reduction of 95% in ATP after 40 
minutes ischemia (118). At the beginning of ischemia, 
the oxidative phosphorylation stops to work, and there is 
a transition from aerobic to anaerobic respiration, which 
may be detectable by observation of the 
electrocardiographic modifications (119) and the 
decrease of the myocardial contractility (120). In the 
myocardium, the activated glycogenolysis is quickly 
slowed down and the intracellular pH may decrease to 6. 
2 after 10 min (121). The cause of the decrease in pH 
during ischemia is not clear (122, 123).  
3.2. Effects of reperfusion 
In the 1960s, R. B. Jennings and cols. (12) and R. A. 
Krug et al. (124) published that reperfusion by itself can 
damage the myocardium previously exposed to ischemia, 
and advanced the pioneering concept of “reperfusion 
injury” (13). These authors showed that if reperfusion is 
applied within 20 min after provoking coronary 
occlusion, myocardial affected is recovered and did not 
die. When ischemia was prolongedto20-40 min before 
institution of reperfusion, subendocardial myocardial 
cells underwent necrosis, but midmyocardial and 
subepicardial cells were salvaged. When duration of 
ischemia extended from 40 min to 3 h, necrosis affected 
in ischemic risk zone from the subendocardium to the 
subepicardium. During this ischemia, it develops the 
phenomenon known as “wave front phenomenon of 
ischemic cell death” (13, 111-114, 125, 126). These ideas 
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are the basis of the current therapy for patients that suffer AMI (Figure 9).  
 
Figure 9. Schematic representation of a fragment of myocardium and an epicardial coronary artery under normal conditions and after 
artery thrombosis with theoretical evolution of myocardium necrosis, non-exposed and exposed to reperfusion. RI=reperfusion injury. 
Acute myocardial infarction is a dynamic process that frequently reaches the total extension of myocardium necrotized within 6 h after 
initiating the artery occlusion.  
Restauration of blood supply to the zone of the 
myocardium exposed previously to ischemia 
(reperfusion) have beneficial effects and also adverse 
effects in the myocardium, by which Braunwald and 
Kloner wrote in 1985 that reperfusion by itself may be a 
“double-edge sword” (11). Reperfusion injury refers to 
myocardial, vascular, and/or electrophysiological 
dysfunction that is induced by the restoration of blood 
flow to previously ischemic myocardial tissue. It is 
recognized four forms of reperfusion injury, of which 
two may be reversible and other two may be irreversible 
(111):  
1) Reversible forms: a) cardiac arrhythmias, 
particularly ventricular arrhythmias, which usually self-
terminate or are easily treated (125), and b) myocardial 
stunning, with contractile ventricular dysfunction as 
consequence of alteration of myocardial contractile 
apparatus (128).  
2) Irreversible forms: a) microvascular plugging, first 
described by Krug et al. in 1966 (124). It may be a 
consequence of capillary damage, endothelial and 
cardiomyocyte cells swelling, micro-embolization of 
material released from the atherosclerotic plaque, micro-
thrombi, release of vasomotor and thrombogenic 
substances, and neutrophil cumulation (129, 130). These 
alterations may be related, at least in part, to the non-
reflow phenomenon, and b) lethal myocardial 
reperfusion injury, characterized by death and apoptosis 
of cardiomyocytes that were viable when reperfusion is 
applied (131, 132 http://www. jci. 
org/articles/view/62874 - B2). Lethal myocardial 
reperfusion injury may account for up to 50% of the final 
myocardial infarction size, and this type of injuries 
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thus represents a target for cardioprotection. At present, 
no effective therapy exists for this situation. It has been 
estimated that timely (early) reperfusion can salvage 
approximately 50% of severely ischemic myocardial and 
that prevention of myocardial reperfusion injury could 
prevent the necrosis of an additional 40% (111).  
Most of studies suggest that the major factors 
contribute to myocardial reperfusion injury are 
intracellular calcium overload, overproduction of radical 
oxygen species, abrupt restoration of pH in ischemic 
zone, and hipercontracture (9, 13, 111, 132). These 
phenomena have been involved in opening a channel in 
the inner mitochondrial membrane (mitochondrial 
permeability transition pore), which permits the entry of 
calcium and radical oxygen species into mitochondria, 
leading to an energetic failure, and death and apoptosis of 
cardiomyocytes. Sarcolemmal disruption may be the 
feature that causes irreversibility, but its pathogenesis is 
at present unknown (9, 13, 111, 132). Figure 10 
summarizes the main intracellular factors involved in the 
effects of ischemia and of reperfusion in the 
cardiomyocytes affected by coronary artery occlusion.  
 
 
Figure 10. Schematic representation summarizing main intracellular changes that may occur in cardiomyocytes after interruption of blood 
supply to a zone of myocardium (Ischemia, left), and after restoration of blood supply to this myocardial ischemic zone (Reperfusion, 
right). 
The available data indicate that not only 
cardiomyocytes but also the coronary vasculature (with its 
endothelium) is damaged after coronary ischemia-
reperfusion. In this condition, the coronary circulation 
deserves attention because of it occupies a central position 
in the cause and consequences of ischemia-reperfusion, 
and it can be damaged in different degrees. This damage 
may vary from moderate impairment of endothelium 
function to severe both functional and structural alterations 
with edema of the vascular wall, and ultimately to vascular 
obstruction and the no-reflow phenomenon. These 
alterations are involved in dysregulation of coronary blood 
flow and functional ability of coronary collaterals, and 
therefore in evolution of ischemia-reperfusion and in 
pathophysiology of reperfusion injury. In consequence, the 
study of coronary vascular and endothelial function after 
ischemia-reperfusion is a focus of interest for investigators 
to understand pathophysiology of reperfusion injury, and 
to improve therapeutical strategies for this condition.  
Several factors, including dysregulation of coronary 
function, increased coronary vascular resistance and 
microvascular obstruction are detrimental for coronary 
perfusion after ischemia-reperfusion. Underlying these 
alterations may be disbalance between endothelial 
vasodilators and vasoconstrictors, coronary 
microembolization, inflammatory cell infiltration and post-
ischemic hyperpermeability. The coronary endothelium is 
one of the victims of ischemia-reperfusion. Since the 
observation by D. D. Ku in 1982 (133) it is known that 
ischemia-reperfusion induces endothelial cell dysfunction, 
with impairment of endothelium-dependent coronary 
vasodilatation and augmented coronary reactivity to 
endothelium-modulated vasoconstrictors. Also, it seems to 
be that the endothelial function may be very sensitive to 
ischemia-reperfusion as it has been observed that after 
brief (15 min) ischemia, coronary vasodilator response to 
Ach was impaired during the first hour of reperfusion and 
gradually improved over a 90-minute, with no evidence of 
endothelium structural damage; in this same study, it was 
found that 20 and 30 minutes of ischemia completely 
impaired endothelium-dependent vasodilation, and 
induced endothelium structural damage (134). Many 
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subsequent studies have confirmed these observations, as 
brief periods of ischemia, including partial ischemia, 
impairs coronary vasodilator responses and enhances 
coronary vasoconstrictor responses, and that these 
alterations are accentuated after prolonged periods of 
ischemia accompanied by myocardial infarction, and they 
affect both epicardial and microvascular coronary 
functional ability (135-140). The mediators of the 
impairment in coronary vasomotor function after ischemia-
reperfusion remain uncertain; it may be involved reactive 
oxygen species (138), plaque rupture with embolization of 
particulate debris and release of vasoconstrictors 
(serotonin, thromboxane (141, 142) ), and inflammatory 
mediators, particularly TNFα (143, 144).  
More recent studies support the idea that NO and ET-1 
play a relevant role at various subclinical and clinical 
stages of the coronary artery disease, and particularly after 
myocardial ischemia-reperfusion. The NO/ET-1 axis could 
play an important role in pathophysiology of myocardial 
ischemia-reperfusion and of reperfusion injury, and 
beneficial effects of some therapeutical strategies for 
myocardial reperfusion injury are attributed to 
modification of this axis. This particular issue, however, 
remains to be resolved and the available results are 
contradictory. As NO and ET-1 may interact for regulating 
the function of coronary vasculature and the myocardium, 
the study of these two substances probably should be 
considered together. NO is produced by both coronary 
endothelial cells and cardiomyocytes, and the principal 
source of this NO is eNOS (NOS3); in cardiomyocites 
NOS1 may be also involved, and expression of both NOS1 
and NOS3 in these cells appears to be species-dependent 
(for this issue, see References 36, 145-148). On the other 
hand, NO seems to play a relevant role in the functional 
regulation of myocardium under normal conditions and 
after ischemia-reperfusion (36, 147-149). Several studies 
demonstrate that biosynthesis of NO by constitutive NOS 
(endogenous NO) plays a critical role in alleviating the 
severity of myocardial ischemia-reperfusion as well as 
reperfusion injury. NO has been known to play various 
functional and pathological roles as an intracellular or 
intercellular messenger in the heart, and there are data 
indicating that NO can both reduce and mediate 
myocardial reperfusion injury. NO influences myocardial 
perfusion by regulating coronary vascular function, 
causing a direct vasodilatory effect and modulating 
vascular reactivity to other types of vasoactive stimuli (e. 
g. ET-1). NO can also influence indirectly myocardial 
perfusion by regulating leukocyte–endothelial cell 
interaction, inhibiting platelet adhesion and aggregation, 
attenuating smooth muscle cell proliferation, and possible 
modulation of cardiomyocytes function. NO released from 
the endothelium has also been shown to inhibit surface 
expression of many endothelial cell adhesion molecules 
(ECAMs), including P-selectin, E-selectin, VCAM-1, and 
ICAM-1 (for this issue, see Reference147). Also, as 
cardiomyocytes are surrounded by capillary endothelial 
cells it allows for cell-to-cell signaling between these two 
types of cells. Interactions between endothelial cells and 
cardiomyocytes could be of significance in regulating 
cardiac function by modulating vascular tone and by 
stimulating proliferation of neighboring cells. This aspect 
may be of relevance in situations such as ischemia and 
reperfusion (149).  
There are studies showing that NO may be detrimental, 
and also studies showing that NO may be critical to 
preserve cardiomyocytes function and viability after 
ischemia-reperfusion. In a Review published by R. Bolli in 
2001 it is indicated that “Of the 92 studies that have 
examined the role of NO in modulating the severity of 
ischemia-reperfusion injury in unstressed myocardium, the 
vast majority (73%) have concluded that NO (either 
endogenous or exogenous) has a protective effect, and 
only 12% found a detrimental effect. The proportion of 
studies supporting a citoprotective role of NO is similar for 
in vivo and in vitro preparations” (150). The cardiac 
interstitial NO concentration may increase during early 
ischemia and early reperfusion, and this increase may be in 
part derived from activated NOS isoforms but also from 
NOS-independent pathways. The cardiac interstitial NO 
concentration is within the nanomolar range during normal 
perfusion. And during ischemia, NOS3 activity is 
increased within minutes, and subsequently the NO 
concentration during early ischemia is increased (151). 
However, with prolonged myocardial ischemia, NOS3 
protein expression decreases, and the tissue acidosis 
attenuates NOS3 activity (153). Within the early seconds 
of reperfusion, the NO concentration is increased (154), 
and if reperfusion is prolonged, NOS activity and thus NO 
concentration decrease below baseline values (155). 
Decreased NO production during reperfusion have been 
suggested by observations indicating loss of NO-
dependent vasodilation in response to Achor bradykinin, or 
loss of vasoconstriction in response to NOS inhibition (for 
details, see Reference 146). During myocardial ischemia-
reperfusion, reduced production of endogenous NO could 
leave unopposed coronary vasoconstriction to the presence 
of vasoconstrictors such as ET-1. This disbalance between 
NO and ET-1 in turn enhances vascular tone, decreases 
coronary blood flow and exacerbates reperfusion injury.  
From the results obtained in a study performed in rat 
hearts, it is suggested that during reperfusion, cardiac 
function is depressed, despite increased rather than 
decreased endogenous NO production, largely due to the 
prevalence of the deleterious effects of ET-1. These 
adverse effects of ET-1 can be overcome by antagonism of 
ET-1 receptors or exogenous NO supplied by NO donors 
(156). In other study performed in anesthetized pigs (157), 
it was examined the interaction between the 
cardioprotective effect of endothelin receptor blockade and 
NO during ischemia-reperfusion injury. The authors of this 
study suggest that blockade of endothelin ETA receptors 
produces cardioprotective effects, and that this 
cardioprotection is mediated via a mechanism related to 
NO (157).  
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In a Review published by R. Schulz et al. in 2004 
(146), the authors remark the importance of endogenous 
and exogenous NO when given at the time of reperfusion 
for vascular and myocardial function, and morphological 
outcome following ischemia-reperfusion. Administration 
of NO, NO donors or drugs that enhance NO release 
(statins, calcium antagonists, angiotensin-converting-
enzyme-inhibitors, dexamethasone) prior to ischemia 
protects the myocardium against ischemia-reperfusion 
injury. This exogenous administration of NO prior to 
ischemia can initiate a preconditioning-like phenomenon. 
Interestingly, in this study it is suggested that endogenous 
NO derived from NO-synthase is not involved in 
triggering or mediating the early phase of ischemic 
preconditioning's protection, but it does play a pivotal role 
for initiating and mediating the delayed phase of ischemic 
preconditioning's protection (146).  
The variation in plasma levels of several factors, 
including ET-1 and NO, was examined in a rabbit model 
of acute myocardial ischemia-reperfusion (158). Rabbits 
were exposed to open-chest surgery and were separated in 
three groups: group A received sham-surgery, group B was 
the reperfusion group, and group C was the infarction 
group. At 12 h and at 24 h after chest closure, plasma 
levels of ET-1 in groups B and C were higher than before 
chest surgery, and at 24 h there was no significant 
difference between these two groups. NO levels in groups 
B and C at 12 h after chest closure were decreased 
compared to those before chest surgery. NO levels in 
group B at 24, 48, and 72 h were lower than those at 12 h, 
while those of group C were not significantly changed 
after 12 h. These results show that ET-1 and NO are 
mutually antagonistic vasoactive substances, and that after 
myocardial ischemia-reperfusion, sustained reduction of 
NO may occur, thus suggesting that NO supplement is a 
good clinical choice. Dynamic monitoring and comparison 
of plasma levels of ET-1 and NO, as well as of other 
factors, revealed that appropriate intervention of these 
factors may reduce reperfusion injury. The authors of this 
same study suggest that plasma ET-1 levels may be used 
as a reference index for the diagnosis and determining the 
prognosis of myocardial infarction. It seems to be that 
endogenousET-1 is increasingly released in systemic 
circulation and coronary circulation, mainly in an 
autocrine/paracrine manner by endothelial cells. This study 
of Zhao et al. (158) also showed that 12 h after myocardial 
ischemia, plasma ET-1 levels increased, while calcitonin 
gene-related peptide (CGRP) levels decreased. Various 
factors and metabolites produced during the early phase 
may have a stimulating effect on endothelial cells, 
increasing the synthesis and release of ET-1, and leading 
to both the consumption and the decreased levels of 
CGRP. From this study (158) it can be inferred that NO 
mediates reperfusion injury, but it also may reduce 
reperfusion injury through its antagonism on the effects of 
ET-1. However, this particular issue requires further 
investigation.  
With regard to mechanisms underly the effects of NO 
after ischemia-reperfusion, several hypothesis have been 
proposed. In relation to the possible protective role of NO 
during ischemia-reperfusion, it has been proposed that it is 
related to the anti-peroxidation effect (156), as well as to 
resistance towards neutrophil adhesion and aggregation 
(159). In relation to NO-mediated myocardial injury, it has 
been suggested that it may be primarily related to 
generation of large amounts of oxygen free radicals as 
consequence of an excess of NO, which reacts rapidly with 
oxygen (154). These circumstances may lead to 
reperfusion injury and aggravate the condition (160). A 
study carried out in cultured cardiomyocytes suggests that 
the enhanced production of NO was critical in balancing 
ATP supply and demand during ischemia, and also in 
protecting cardiomyocytes from ischemia-reperfusion 
injury (161).  
The development of gene-targeted mice has allowed to 
begin to define the cellular and molecular mechanisms 
involved in the pathogenesis of acute myocardial 
infarction, although the results from these experimental 
models should be taken with caution. The development of 
mice with genetic manipulations could provide useful 
information regarding pathologic mechanisms related to 
myocardial ischemia-reperfusion injury (for details, see 
Reference 147). Studies using a model of eNOS transgenic 
mice have demonstrated that eNOS overexpression 
significantly attenuates the extent of myocardial infarct 
size following coronary artery ischemia and reperfusion 
(162).  
Summarizing, the studies exposed before suggest that 
the role of NO in ischemia-reperfusion and reperfusion 
injury is not clear as there are data suggesting that NO may 
be beneficial and that it may be detrimental in evolution of 
myocardial ischemia-reperfusion. As hypothesis, it might 
be that at the beginning of reperfusion the presence of NO 
might be beneficial, particularly for coronary vascular 
vasomotion, but at chronic stage its presence might be 
pernicious for heart tissue because of it would facilitate 
formation of free radical species.  
With regard to ET-1, many data suggest that this 
peptide is involved in the pathophysiology of reperfusion 
injury (67, 68, 163-166), and that it may be also a 
significant predictor of reperfusion injury (167, 168). 
During ischemia-reperfusion, the production of ET-1 is 
increased, the coronary vasoconstrictor effects of this 
peptide are also increased, and ET-1 enhances myocardial 
necrosis and arrhythmogenesis (67, 68, 80). Plasma ET-1 
levels increase 3–4h after the onset of ST segment 
elevation myocardial infarction, peak within the first 24h 
and remain elevated after 48h (168). High ET-1 values 
after percutaneous coronary intervention have been linked 
to poor prognosis, including higher 30-day mortality (168). 
In humans, evidence of microvascular injury has been 
obtained as angiographic scores, primarily by indirect 
methods such as the thrombolysis in myocardial infarction 
grade flow and myocardial blush grade (169) and more 
recently by cardiac magnetic resonance (170). Results 
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from patients suggest that high plasma ET-1 levels after 
myocardial infarction are associated with the presence of 
microvascular obstruction and lower myocardial salvage 
index (171).  
An interesting study was performed in patients with 
AMI that underwent reperfusion therapy or conservative 
drug therapy. Patients who underwent reperfusion therapy 
had significantly lower eNOS and NO levels, and higher 
plasma ET-1 levels than those who received conservative 
drug therapy. All patient groups had significantly lower 
eNOS and NO levels, and higher ET-1 levels, than healthy 
controls. There was a significant positive correlation 
between eNOS and NO, as well as significant negative 
correlations between eNOS/ET-1 and NO/ET-1 (172). In 
other study it has been found that the circulating level of 
ET-1 was considerably higher in the non-spontaneous 
reperfusion patients than in the spontaneous reperfusion 
patients; the ET-1 level was the only significant predictor 
of spontaneous reperfusion, and the ET-1 level at 
admission is an indicator of spontaneous reperfusion (173). 
L. Cao et al. (174), after considering observations by 
others, suggest that ET-1 may act as a negative factor in 
reperfusion injury. These authors also suggest that ET-1 
plays a different role in the different stages of myocardial 
ischemia-reperfusion, and to ascertain the exact 
mechanisms, experimental and clinical studies are needed 
(174). On the other hand, it can not be excluded that after 
ischemia-reperfusion, ET-1 also may induce beneficial 
effects on the myocardium. ET-1 could induce 
cardioprotection against infarct size and ventricular 
arrhythmias, through as yet incompletely understood 
mechanisms (175), as well subsequent infarct-healing and 
early ventricular remodeling (166, 176).  
Data from literature suggest that ET-1 plays a relevant 
role in development of coronary artery disease and in the 
effects of myocardial ischemia-reperfusion (Figure 11). 
 
Figure 11. Schematic representation of the probable role of ET-1 in the pathophysiology of coronary artery disease, myocardial 
infarction, and heart failure. At preclinical stages, ET-1 could contribute to endothelial cell dysfunction and to atherosclerosis. During 
acute coronary syndromes, ET-1 could cause adverse effects (vasoconstriction, inflammation, myocardial necrosis, arrhythmogenesis), 
and during chronic evolution it might have beneficial effects by participating in infarct healing.  
The study of the effects of ET-1 and its interaction with 
NO in coronary vasculature after ischemia-reperfusion 
may contribute to know its pathophysiology. Respect to 
this issue, most of studies have been related with the 
analysis of the effects of total ischemia followed by 
reperfusion, and very few studies have been performed 
about the effects of partial ischemia alone or followed by 
reperfusion. The clinical situation of partial ischemia of 
the myocardium may be present in patients with coronary 
atheromatosis, dynamic vasospasm, or transient arterial 
hypotension.  
During reperfusion after total (134) or partial (140) 
coronary occlusion, endothelium-dependent coronary 
vasodilatation is decreased. Also, basal release of NO from 
isolated, perfused rat hearts may be diminished after global 
ischemia-reperfusion, with implication of the NO pathway 
(177). On the hand, administrations of exogenous NO 
diminish the adverse effects of ischemia-reperfusion (178). 
Other studies, however, showed that inhibitions of NO 
synthesis may protect, rather than aggravate, the effects of 
ischemia-reperfusion (18, 179). For ET-1, ischemia-
reperfusion can induce increased coronary 
vasoconstriction in response to this peptide (180) but 
whether or not this increased effect is present may depend 
on the severity and duration of ischemia (181). The 
increased response to ET-1 after ischemia-reperfusion it 
has been attributed to decreased production of NO and 
prostacyclin as a result of endothelial dysfunction, and of 
changes in characteristics of endothelin receptors in 
coronary vessels (180, 182). The coronary reactivity to 
ET-1 after ischemia-reperfusion has been explored mainly 
using in vivo and in vitro preparations, and coronary 
ischemia for different periods has been induced in vivo by 
occluding one coronary artery and in isolated, perfused 
hearts.  
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In our laboratory, we found in anesthetized goats that 
during partial occlusion of the left circumflex coronary 
artery, coronary vascular conductance was reduced by 
about 30%, and the coronary vasodilatation in response to 
Achand sodium nitroprusside was decreased in animals 
non-treated or treated with L-NAME or with 
meclofenamate; the vasoconstriction in response to ET-
1 was depressed in non-treated animals, and this 
depression was reversed by L-NAME and was accentuated 
by meclofenamate. At 30 min of reperfusion after this 
partial coronary occlusion, coronary vascular conductance 
remained decreased by about 25%, and the vasodilatation 
in response to Achand sodium nitroprusside, as well as the 
vasoconstriction with ET-1 were as in the control and were 
comparable in treated and non-treated animals. These 
results suggest: a) that during partial ischemia, 
the coronary vasodilator reserve is greatly reduced, and the 
vasoconstriction to ET-1 is blunted, with preservation of 
the modulatory role of NO and involvement of 
vasoconstrictor prostanoids in this vasoconstriction, and 2) 
that during its reperfusion, the coronary vasodilator reserve 
and the coronary reactivity to Ach and ET-1 recover, but 
the modulatory role of NO in this reactivity may be 
attenuated (183).  
We also explored the effects of reperfusion after short 
and prolonged, total ischemia on the role of NO and the 
effects of ET-1 in the coronary circulation. In this case, 15- 
or 60-min total occlusion of the left circumflex coronary 
artery was induced in anesthetized goats. In non-treated 
animals, during reperfusion after 15-min occlusion, the 
ET-1-induced coronary effects were lightly increased, and 
the effects of Ach were unchanged. During reperfusion 
after 60-min occlusion, the ET-1-induced effects were 
more pronounced, and the effects of Ach were decreased. 
L-NAME treatment did not modify the coronary effects of 
ET-1 during reperfusion after both occlusion durations. 
This treatment inhibited the effects of Ach during 
reperfusion after 15-min, and after 60-min occlusions. 
Meclofenamate treatment did not modify the coronary 
effects of ET-1 and Ach during reperfusion after both 
occlusion durations. Thus, ischemia-reperfusion could 
increase the coronary response to ET-1, which is more 
pronounced during reperfusion after prolonged than after 
brief ischemia, and that this increased response to ET-1 is 
probably related to inhibition of NO release, without 
involvement of prostanoids (184). Figure 12 shows an 
estimation of the role played by NO in the regulation of 
the coronary circulation under normal conditions and after 
ischemia-reperfusion (183, 184).  
 
 
Figure 12. Estimation of the role played by NO in the regulation of the coronary circulation under normal conditions, after partial 
coronary occlusion followed by reperfusion (PI+R), after 15 min of total coronary occlusion followed by reperfusion (TI15+R) and after 
60 min of total coronary occlusion followed by reperfusion (TI60+R). These estimations are based on data obtained in experiments with 
Ach and ET-1 in anesthetized goats (References 183, 184).  
To compare the coronary response to ET-1 with the 
response to other vasoconstrictor after ischemia-
reperfusion, we explored the coronary effects of arginine–
vasopressin (AVP). This hormone may be of significance 
in the regulation of coronary circulation as it can produce 
coronary vasoconstriction (185), which can be severe 
enough to cause myocardial ischemia (186). This peptide 
also could be of interest for understanding the 
pathophysiology of myocardial ischemia-reperfusion as 
human plasma levels of AVP are augmented after 
myocardial infarction (187), and during reperfusion after 
myocardial infarction (188). Studies performed in dogs 
show that the coronary effects of AVP are increased in the 
ischemic myocardium, which can worsen hypoperfusion of 
collateral-dependent myocardium during exercise (189). 
Sellke and Quillen (190) report that the coronary action of 
AVP is augmented after ischemia alone or followed by 
reperfusion, and the authors suggest that this augmented 
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effect might be related to alteration of release of NO and 
prostanoids.  
In pages 26 and 27, we have commented two studies 
from our laboratory where we found that under normal 
conditions AVP produces marked coronary 
vasoconstriction and that this vasoconstriction may be 
mainly mediated by vasopressin V1 receptors, and it is 
modulated by NO, but not by prostanoids (98). In the other 
study, we compared the coronary effects of ET-1 and 
AVP, and the results show that ET-1 produce higher 
vasoconstrictor effect than AVP. From this study, it is also 
suggested that NO may play a more relevant role for 
modulating the coronary vasoconstriction by ET-1 than by 
AVP, and that cyclooxygenase products may not be 
involved in the coronary effects of these two peptides 
(100) (See Figure 7). We then examined the coronary 
effects of AVP and its interaction with NO and prostanoids 
during ischemia and reperfusion. During partial coronary 
occlusion, the coronary vasoconstriction in response to 
AVP was attenuated in non-treated animals, and this 
attenuation was reversed by L-NAME and was 
accentuated by meclofenamate. At 30 min of reperfusion 
after this partial coronary occlusion, the vasoconstriction 
with AVP was as in the control and this vasoconstriction 
was not affected by L-NAME or meclofenamate. These 
results suggest that: 1) during partial ischemia, the 
coronary vasoconstriction with AVP is attenuated, with 
preservation of the modulatory role of NO and probable 
involvement of vasoconstrictor prostanoids in this 
vasoconstriction; and 2) during its reperfusion, the 
coronary reactivity to AVP recover, but the modulatory 
role of NO in this reactivity may be attenuated. The 
significance of these results may be that the endothelial 
function in modulating coronary reactivity to AVP is very 
sensitive to reperfusion after partial, moderate ischemia, 
and that AVP may also contribute to the adverse effects of 
ischemia-reperfusion on coronary vasculature (191). In 
other series of experiments, we found that at 60 min of 
reperfusion after 15 min total occlusion of the circumflex 
coronary artery, the coronary vasoconstriction in response 
to AVP was increased during reperfusion in non-treated, 
was not changed in L-NAME-treated and was decreased in 
meclofenamate-treated animals. Therefore, this study 
suggests that during reperfusion after a short, total 
ischemia, the coronary vasoconstriction in response to 
AVP is increased, probably due to both attenuation of the 
modulatory role of NO and the release of vasoconstrictor 
prostanoids (192). This idea is in line with that proposed 
by others (189, 190), and both of them suggest that AVP 
should be considered as a factor involved in 
pathophysiology of myocardial ischemia-reperfusion, 
although its role could be of less significance than that of 
ET-1.  
We also explored the coronary vasodilator reserve after 
ischemia-reperfusion examining the hyperemic response 
after brief coronary occlusions. To this, partial (60 min) or 
total (15 and 60 min) occlusions of the left circumflex 
coronary artery were induced, followed in each case by 60-
min reperfusion in anesthetized goats, untreated and 
treated with L-NAME or meclofenamate. Coronary 
occlusions of 5- and 10-s duration produced hyperemic 
responses that depended on occlusion duration. After 
ischemia-reperfusion, these hyperemic responses were 
diminished, and this diminution was dependent on duration 
and severity of ischemia. These effects of ischemia-
reperfusion were not affected by inhibition of NO 
synthesis with L-NAME, and were reversed with 
meclofenamate. The hyperemic response reduction during 
reperfusion after prolonged ischemia, but not after brief 
ischemia may be related at least in part to increased 
production of vasoconstrictor prostanoids (193).  
Episodes of myocardial ischemia may occur in humans 
under situations such as transient arterial hypotension. 
From experiments in anesthetized dogs it has been 
reported that the coronary reactivity to ET-1, but not to 
angiotensin II is increased during low coronary perfusion 
pressure, which may contribute to coronary ischemia after 
reduced coronary perfusion (194), and that ET-1 does not 
modify the coronary response to decreased coronary 
perfusion pressure after coronary stenosis (195). 
Hemorrhagic shock in rats is accompanied by decreased 
perfusion of the heart (and other organs), together with 
increased ET-1 levels in plasma (196). As a result, the 
authors suggest that ET-1 is involved in the decreased 
perfusion of vital and peripheral tissues during 
hemorrhagic shock (196). Experimental observations have 
shown that ET-1 (197) and AVP (187) may increase in 
plasma during some types of hypotension. It seems that 
under normotension NO may be more relevant in 
modulating coronary vasoconstriction by ET-1 than by 
AVP (191), and that NO and ET-1 mutually affect the 
production and action of each other in the blood vessel 
wall (198). We performed experiments in anesthetized 
goats where blood flow through the left circumflex 
coronary artery was measured electromagnetically, and 
hypotension was induced by constriction of the caudal 
vena cava. ET-1 and AVP were directly injected into this 
coronary artery before (normotension) and during 
hypotension in animals non-treated and treated with L-
NAME, meclofenamate, or both inhibitors. The results of 
these experiments suggest that hypotension increases the 
coronary vasoconstriction in response to ET-1 but not to 
AVP. This increased response to ET-1 may be related to 
both inhibition of NO release and of vasoconstrictor 
prostanoids release. This study also suggests that in the 
coronary circulation, the functional interaction between 
NO and ET-1 may be greater than that between NO and 
AVP (199).  
To extend our knowledge of the coronary effects of 
ET-1 after ischemia-reperfusion, the left anterior 
descending coronary artery of anesthetized pigs was 
subjected to 30-min occlusion followed by 60-min 
reperfusion. Then, rings distal (ischemic arteries) and 
proximal (control arteries) to the artery occlusion were 
taken from this artery and prepared for isometric tension 
recording. The sensitivity of the contractile response to 
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ET-1 and to the endothelin ETB receptor agonist IRL-1620 
was augmented in ischemic vessels. The endothelin ETA 
receptor antagonist BQ-123 decreased the sensitivity of the 
response to ET-1 similarly in ischemic and control arteries. 
The endothelin ETB receptor antagonist BQ-788, 
endothelium removal or L-NAME potentiated the response 
to ET-1 and to IRL-1620 in control arteries but not in 
ischemic arteries. Meclofenamate augmented the maximal 
response to ET-1 in control arteries, and reduced it in 
ischemic arteries. In precontracted arteries, IRL-1620 
relaxed control but not ischemic arteries, and L-NAME or 
meclofenamate abolished this relaxation. Therefore, 
ischemia-reperfusion increases the coronary 
vasoconstriction in response to ET-1 probably due to 
impairment of endothelin ETB receptor-induced release of 
NO and prostacyclin, to augmentation of the contractile 
response to activation of endothelin ETB receptors, and to 
increased release of vasoconstrictor prostanoids (200). 
Studies by others were performed in male Sprague-Dawley 
rats, which were subjected to either heart ischemia–
reperfusion (15 min ischemia and 22 h reperfusion), 
permanent ischemia (22 h) by ligation of the left anterior 
descending coronary artery, or sham operation (201). 
Then, the endothelin receptor subtypes mediating 
vasoconstriction were examined in isolated segments of 
the left anterior descending and the non-ligated septal 
coronary arteries. Endothelin ETB receptor-mediated 
vasoconstriction and receptor protein levels were 
augmented in coronary arteries exposed to ischemia–
reperfusion. In contrast, the ETA receptor-mediated 
vasoconstriction was unaltered in all groups. It is 
suggested that ischemia–reperfusion induces local up-
regulation of ETB receptors in the smooth muscle cells of 
coronary arteries in the post-ischemic area. In contrast, in 
non-ischemic areas, endothelin ETB receptor function was 
unaltered (201). In a revision published in 2010, Nguyen et 
al. (80) suggest that the beneficial role of endothelin ETB 
receptors present under normal conditions may decline 
with age and risk factors for cardiovascular diseases, 
revealing smooth muscle ETB-receptors with pro 
constricting and proinflamatory activities.  
We also studied the effects of ischemia-reperfusion on 
coronary vasculature using isolated, perfused hearts from 
rats. After 15, 30 or 45 min of global zero-flow ischemia 
and 15 min reperfusion, the coronary vasoconstriction 
induced by ET-1 increased after 15 min of ischemia, but 
not after 30 or 45 min of ischemia. Inhibition of NO 
synthesis with L-NAME augmented the vasoconstriction 
induced by ET-1 in non-ischemic hearts, but not following 
ischemia. These results suggest that in this experimental 
preparation, ischemia-reperfusion also inhibits NO 
production, causing an increased coronary response to ET-
1 after brief ischemias. Longer ischemias may non-
specifically inhibit coronary vasoconstriction and reduce 
NO production (202). In other series of experiments 
carried out in isolated, perfused hearts from rats exposed to 
30 min global zero-flow ischemia followed by 15 min 
reperfusion (203), we found that after ischemia-
reperfusion, 5-hydroxytryptamine produced contraction in 
isolated coronary arteries, which was potentiated by 
treatment with ET-1. This potentiation by ET-1 was lower 
after ischemia-reperfusion than after control, and the 
potentiation was reduced by l-NAME, by blockade of 
endothelin ETA receptors with BQ123 and by blockade of 
endothelin ETB receptors with BQ788, but not by the 
cyclooxygenase inhibitor meclofenamate. Thus, ET-1 at 
low concentrations could potentiate coronary 
vasoconstriction, and this effect is reduced after ischemia-
reperfusion, mediated by both endothelin ETA and ETB 
receptors and is dependent on NO release. This suggests 
that ischemia-reperfusion might induce complex effects on 
the coronary vascular effects of ET-1 (203).  
We have also explored the effects of ischemia-
reperfusion on the coronary reactivity to other types of 
substances, the effects of which may be dependent on the 
endothelium and may be of interest in the context of 
ischemia-reperfusion. Between these substances are 
diadenosine polyphosphates (ApnAs), which are molecules 
that have a chain of 2-6 phosphate groups and they may 
produce vasodilatation or vasoconstriction of blood vessels 
depending on the particular ApnA in question. In the 
coronary circulation, ApnAs produce vasodilation in pigs 
(204) and in dogs (205) when they are present at nM to 
mM concentrations, as may exist in plasma under normal 
conditions. Platelet activation and platelet release of 
ApnAs, may be involved in the pathophysiology of 
ischemia-reperfusion (206), and the concentration of 
ApnAs may increase in coronary venous blood during 
ischemia-reperfusion (207). As these substances can 
produce vasodilatation or vasoconstriction depending on 
the conditions of coronary blood vessels, these compounds 
could participate in the altered coronary regulation 
associated with ischemia-reperfusion. Apn5A has a long 
phosphate chain and it is more likely to produce 
vasoconstriction and therefore, to be involved in the 
coronary vasoconstriction that frequently occurs after 
ischemia–reperfusion. Moreover, the production of Ap5A 
in the heart is increased during heart ischemia. Compared 
to control rat hearts, the coronary vasoconstriction to 
Ap5A was augmented and vasodilation diminished after 
ischemia–reperfusion. After testing the effects of 
antagonists for P2 and P2Ypurinoceptors, L-NAME and 
meclofenamate, it is suggested that ischemia–reperfusion 
reduces the coronary vasodilatory response and increases 
the coronary vasoconstriction to Ap5A, due to a reduced 
influence of purinergic P2Y receptors and/or to the 
production of vasoconstrictor prostanoids (208). The 
studies with triphosphate (Ap3A) showed that this 
substance produces coronary vasodilation in control rat 
hearts, which was attenuated following ischemia-
reperfusion. In this case, the results suggest that the 
attenuation of the coronary vasodilatation to Ap3A after 
ischemia-reperfusion could be due to the functional 
impairment of purinergic P2Y receptors and K (ATP) 
channels, and/or reduced NO release in this condition 
(209). Tetrataphosphate (Ap4A), in control rat hearts, 
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produced vasodilatation, which was reduced by reactive 
blue 2, glibenclamide, and endothelin-1, but was not 
affected by L-NAME. After ischemia-reperfusion, the 
vasodilatation to Ap4A diminished, and in this case the 
relaxation to Ap4A was not modified by reactive blue 2, 
L-NAME, glibenclamide, although it was reduced by 
endothelin-1. These results suggest that the reduction of 
the coronary relaxation to Ap4A after ischemia-
reperfusion may be due to impaired effects of KATP 
channels and to reduced response of purinergic P2Y 
receptors (210). These three studies (208-210) also show 
data suggesting that purinergic receptors may be a way 
involved in the coronary response to some vasoactive 
substances and this way may be altered after ischemia-
reperfusion. Interestingly, purinergic receptors may be also 
involved in the coronary vasodilatation in response to Ach 
after ischemia-reperfusion, but not under control 
conditions. The role of purinergic receptors in the coronary 
vasodilation in response to Ach may be developed in 
coronary vasculature during ischemia-condition in order to 
compensate the reduction of NO release in this condition 
(211).  
Summarizing, the data exposed before suggest that 
ischemia-reperfusion alters the regulation of the coronary 
circulation, which may be induced, in part, by 
dysfunction/damage of the endothelium. This alteration 
could lead to modification of the normal balance between 
NO and ET-1 that exists under normal conditions for the 
control of coronary vascular tone. After ischemia-
reperfusion, the role of NO is reduced, whereas that of ET-
1 is augmented, which may have pernicious effects for the 
functional capacity of coronary vasculature, as for example 
this vasculature could exhibit an exaggerated 
vasoconstrictor and inflammatory response, thus 
contributing to the presence of the non-reflow 
phenomenon. Therefore, the damage of the endothelium, 
with the consequent alteration in the interaction between 
NO and ET-1 may play a crucial role in pathophysiology 
of disregulation of coronary circulation and of the non-
reflow phenomenon after ischemia-reperfusion, and in 
pathophysiology of reperfusion injury. Also, these two 
substances by forming a functional axis that acts on the 
coronary artery wall, probably should be considered 
together in analyzing pathophysiology of myocardial 
ischemia-reperfusion and reperfusion injury, as well as in 
therapeutical approaches for mitigating reperfusion injury.  
4. THERAPEUTICAL APPROACHES FOR 
REPERFUSION INJURY 
In an elegant article, E. Braunwald published that 
during the last 100 years, approximately, the management 
of AMI has gone through fourth major phases (9). These 
phases are summarized as follows: The past: a) phase I: the 
management was limited to bed rest, morphine for pain, as 
well as digitalis, caloric and fluid restriction, and expectant 
treatment; b) phase 2: it began in 1961 with a paper by 
Desmond Julian, where he described what later would be 
known as the Coronary Care Unit (212). In these Units the 
patients were monitorized, and they were attendant by 
training of medical and nursing staff, providing trained 
nurses with the authority and responsibility to perform this 
procedure, including external defibrillation, in the absence 
of a physician. Phase 3 (The Present): It is the phase of 
myocardial reperfusion which was initiated in 1975 by 
Chazov et al. who lysed coronary thrombi by infusing 
streptokinase directly into the blocked coronary arteries of 
patients with AMI (6), and it was demonstrated that timely 
reperfusion actually salvaged ischemic myocardium (213). 
During the last quarter century, myocardial reperfusion has 
been improved progressively by a number of key steps. 
However, although myocardial reperfusion represents a 
major advance in the treatment of myocardial infarction, 
this procedure is often accompanied by myocardial injury, 
so that E. Braunwald and R. A. Kloner referred to 
myocardial reperfusion as ‘a double-edged sword (10). 
Phase 4 (The Future): the prevention of myocardial 
reperfusion injury. Many interventions to prevent or 
diminish myocardial reperfusion injury have been studied 
(214). It has been estimated that timely, adequate 
reperfusion can salvage approximately 50% of severely 
ischemic myocardium (215), and that prevention of 
myocardial reperfusion injury should prevent the necrosis 
of an additional 40% (112). Nevertheless, further 
experimental and clinical research on myocardial 
reperfusion injury should be carried out (9).  
The prognosis of AMI largely depends on its extent, 
and the final necrotic extent is mostly due to the speed of 
the progression of ischemic injury and the duration of the 
ischemia (215, 216). The most effective treatment to limit 
infarct size is early reperfusion, and the window in which 
reperfusion effectively limits infarct size in patients with 
ST segment elevation myocardial infarction is short. After 
3 h of ischemia, without collateral circulation and residual 
flow, the amount of salvaged myocardium is small or 
nonexistent (217). Nonetheless, late reperfusion may be 
also beneficial, and should generally be performed within 
12 h of symptoms onset (218). In this case, however, the 
benefit is due to the positive effects of reperfusion on 
healing of myocardium damaged (218).  
Protect patients against myocardial damage caused by 
ischemia-reperfusion has became a public health problem. 
Because the best strategies against the morbidity and 
mortality of AMI is to minimize the ischemic death of 
myocardial tissue, there are a notable interest for 
investigating and learning how the heart can be protected 
from ischemic death. The development of new approaches, 
including new techniques, as well as the discovery of 
novel drugs could provide means for new ways of heart 
protection against ischemic myocardial injury. About this 
particular issue, several and revisions are available (9, 122-
124, 217-220).  
A number of therapeutic strategies for preventing 
myocardial reperfusion injury have been developed. In 
general, they can be grouped in two ways: a) non-
pharmacological strategies (conditioning phenomena: 
ischemic preconditioning (IPC), ischemic postconditioning 
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(IPOC), and remote ischemic preconditioning (RIPC) ); 
and b) pharmacological strategies (use of drugs).  
4.1. Conditioning phenomena 
IPC: Observations showed that reperfusion salvages 
ischemic myocardium from infarction, and that infarction 
spreads in a wave front during ongoing ischemia but 
leaves salvageable myocardium up 2-3 hours. Then, Murry 
et al. in 1986 came up with the ingenious idea to perform 
short cycles of ischemia-reperfusion before a prolonged 
ischemic insult and found that this maneuver attenuated 
myocardial infarct size (221), thus establishing the prime 
cardioprotective paradigm of IPC. Further studies showed 
that IPC has two different temporal forms: an acute form 
which confers immediate protection but vanishes after an 
interval of about 2 hours between the preconditioning 
stimulus and the event that need protection, and a delayed 
form which reappears after 24-48 hours, lasts longer but is 
less protective (222). The acute form of IPC relies on the 
recruitment of acutely available signaling modules, 
whereas the delayed form involved increase expression of 
protective proteins in response to an acute signal (223). 
IPC has been translated to human beings with ischemic 
heart disease but because of its nature it can not be used un 
patients with AMI, and it can be used only in situations as 
percutaneous coronary interventions and coronary artery 
bypass grafting (220, 224).  
Protection of coronary vascular function by IPC is 
uncertain as there are results indicating that this procedure 
preserves coronary vasomotion, whereas other results do 
not (see Reference 14).  
IPOC: Modification of reperfusion can attenuate 
reperfusion injury and thus reduce infarct size. This 
procedure refers to intermittent reperfusion of the acute 
ischemic myocardium, which has been reported to prevent 
myocardial reperfusion injury and reduce myocardial 
infarction size by 40%–50% (122). IPOC was established 
by Z. Q. Zhao et al. (225) who experimentally observed 
that 3 cycles of 30 sec reperfusion/30 sec reoclusion at the 
immediate onset of reperfusion after 60 min of coronary 
occlusion reduced infarct size to a similar amount that with 
IPC. This seminal study was followed by others. IPOC is 
limited to the early minutes of reperfusion, and it has been 
successfully translated to human beings with ischemic 
heart disease, and can be used in patients undergoing 
interventional reperfusion of AMI (224). Staat et al. (226) 
first applied IPOC to the clinical setting of percutaneous 
coronary artery: immediately after direct stenting, 
coronary blood reflow was allowed for 60 seconds, 
following which the angioplasty balloon was inflated 
upstream of the stent for 60 seconds to occlud coronary 
blood flow, and this cycle was repeated 4 times in total. 
The results of this study confirmed the existence of lethal 
myocardial reperfusion injury in humans (227), but a 
number of clinical studies have subsequently confirmed 
the beneficial effects of IPOC, although not all studies 
have had positive results. Protector effects of IPOC on 
coronary vasculature functionary unclear (see Reference 
14).  
RIPC: IPOC requires an invasive therapeutic 
intervention applied directly to the heart. However, the 
heart can be protected against acute ischemia-reperfusion 
injury from a distance, by applying one or more cycles of 
brief, nonlethal ischemia and reperfusion to another organ 
or tissue, a phenomenon that has been termed remote 
ischemic conditioning (RIPC) (228). In the clinical setting, 
RIPC has been achieved noninvasively by simply inflating 
and deflating a blood pressure cuff placed on the upper 
arm to induce three 5-minute cycles of ischemia and 
reperfusion (229). This therapeutic approach has been 
reported to be beneficial in patients undergoing cardiac 
surgery and in patients undergoing elective percutaneous 
coronary interventions. More recently, Botker et al. (230) 
demonstrated that RIPC applied by a paramedic to patients 
with ST segment elevated myocardial infarction in transit 
to the percutaneous coronary interventions center 
improved myocardial salvage compared with control 
patients. A recent review and meta-analysis of clinical 
studies shows that RIPC could be an effective method for 
reducing myocardial ischemia-reperfusion injury (231).  
These conditioning procedures exert significant 
cardioprotection, but they may be injurious per se, and a 
better understanding of the signal transduction under 
laying the conditioning phenomena may help to make 
more beneficial the application of these techniques. A 
review about signaling molecules and mechanisms in 
conditioning (physical and chemical triggers, intracellular 
signal transduction) can be found in References 220 and 
232. Cardioprotective signal transduction appears as a 
highly concerted spatiotemporal program, and the general 
consensus is that mitochondria are the most important 
effector of protection of conditioning, where most of 
signaling pathways may converge (220, 232). Although 
the translation of IPC and RIPC protocols to patients with 
acute myocardial infarction has been fairly successful, the 
pharmacological recruitment of cardioprotective signaling 
has been largely disappointing to date.  
4.2. Pharmacological strategies 
Several studies to prevent reperfusion injury by means 
of pharmacological agents have been conducted. Factors of 
importance are the timing of drug administration, animal 
species used, degree of collateral flow and the duration of 
ischemia. A variety of pharmacological compounds have 
been investigated in different experimental models of 
myocardial ischemia and reperfusion.  
Considering the factors that may contribute to the 
deleterious effects of myocardial ischemia-reperfusion, 
pharmacological strategies tested are summarized as 
follows: 
A)  Against oxidative stress. Within a few minutes of 
myocardial reperfusion, a burst of oxidative stress (233) is 
produced by a variety of sources. This oxidative stress 
mediates myocardial injury and cardiomyocyte death 
through a number of different mechanisms. Based on these 
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observations, antioxidant therapy was considered to be an 
appropriate option to prevent such injury. However, both 
experimental and clinical studies have reported mixed 
results with the administration of antioxidant therapy at the 
onset of myocardial reperfusion (234). However, the 
discovery of mitochondrial-specific antioxidants may be 
more effective (235).  
B)  Against intracellular Ca2+ overload. Ca2+ 
overload begins during acute myocardial ischemia and is 
exacerbated during myocardial reperfusion, and this 
overload induces the opening of the mitochondrial 
permeability transition pore. Experimental studies have 
shown that pharmacologic antagonists of the sarcolemmal 
Ca2+ channel (236) or the mitochondrial Ca2+ uniporter 
(237) administered at the onset of myocardial reperfusion, 
reduces infarct size by up to 50%. However, not all 
experimental studies using this therapeutic strategy have 
been positive. Clinical studies of Ca2+ channel blockers 
administered at the onset of myocardial reperfusion have 
not shown beneficial results (238). The identification of 
the mitochondrial Ca2+ uniporter may result in the 
discovery of a new class of specific inhibitors for targeting 
lethal myocardial reperfusion injury.  
C)  To slow the restoration of physiological pH. 
During acute myocardial ischemia the intracellular pH 
decreases to <7. 0, where as at reperfusion, physiological 
pH is rapidly restored by the washout of lactate and the 
activation of the Na+-H+ exchanger, as well as the Na+-
HCO– symporter. This pH shift contributes to the 
cardiomyocyte death of lethal myocardial reperfusion 
injury by permitting mitochondrial permeability transition 
pore opening and cardiomyocyte rigor hypercontracture in 
the first few minutes of reperfusion. Reperfusion of 
ischemic animal hearts with an acidic buffer can reduce 
infarct size (239). Therefore, a potential treatment strategy 
for preventing lethal myocardial reperfusion injury would 
be to slow the normalization of physiologic pH at the time 
of myocardial reperfusion or by slowing the process of 
myocardial reperfusion, as in the case of ischemic 
postconditioning (122).  
D)  The mitochondrial permeability transition pore 
(MPTP) as a target for cardioprotection. The MPTP is a 
nonselective channel of the inner mitochondrial 
membrane, the opening of which results in mitochondrial 
membrane depolarization and uncoupling of oxidative 
phosphorylation, leading to ATP depletion and cell death. 
As such, preventing MPTP opening at the time of 
reperfusion by administering MPTP inhibitors (e. g., 
cyclosporin A) at the onset of myocardial reperfusion has 
been reported in experimental studies to reduce infarct size 
by 40–50% in animal myocardial infarction models (240). 
Thus, MPTP may be an important therapeutic target for 
preventing lethal myocardial reperfusion injury (122).  
E)  Against inflammatory response. It is unclear 
whether the inflammatory response that accompanies an 
AMI contributes to the pathogenesis of lethal myocardial 
reperfusion injury or whether it is a reaction to the acute 
myocardial injury. Although experimental studies have 
reported significant reduction of infarct size by inhibiting 
the inflammatory process at the time of myocardial 
reperfusion and the inhibition of complement activation, 
corresponding clinical studies using this therapeutic 
approach have been largely negative (122).  
F)  Against late myocardial reperfusion injury. Some 
of the described stimulators of myocardial reperfusion 
injury all appear to operate in the first few minutes of 
myocardial reperfusion, providing a narrow window for 
reducing infarct size in patients. However, several other 
important processes such as apoptosis and inflammation, 
which are also initiated during ischemia and continue over 
several hours into reperfusion, may contribute to the 
development of lethal myocardial reperfusion injury. 
These contributing pathways provide a potential second 
therapeutic window for reducing infarct size. However, 
this is a controversial area of research, and some 
experimental studies have failed to demonstrate an 
increase in infarct size with reperfusion time. Several 
experimental studies have reported that administering 
cardioprotective agents such as erythropoietin (anti-
apoptotic), PI3K-γ/δ inhibitors (anti-inflammatory), and 
intracoronary aqueous oxygen, from 30 minutes to 24 
hours into myocardial reperfusion may still limit acute 
myocardial infarct size at 72 hours. This may provide an 
additional therapeutic window to target late into the 
reperfusion phase (122).  
G)  Antagonists for endothelin ETA and ETB 
receptors. As ET-1 may have a relevant role in 
pathophysiology of myocardial ischemia-reperfusion, this 
has stimulated the possible beneficial effects of 
endothelin-receptor-blockade to protect the heart against 
reperfusion injury. However, this research has yielded 
unclear results. Respect to this issue, it could be of interest 
to take in mind the probable interaction between NO and 
ET-1.  
Efficacy of the non-selective endothelin antagonist l-
753037 was examined in a model of canine coronary 
artery occlusion and reperfusion to assess whether 
blockade of both ETA and ETB receptors would enhance 
or reduce myocardial ischemic injury. The results suggest 
that this non-selective endothelin antagonist provides 
significant myocardial protection primarily by improving 
regional myocardial flow distribution following 
reperfusion, and demonstrated no detrimental effects 
associated with blockade of the ETB receptor (241).  
Endothelin ETA and ETB receptor antagonists could 
be cardioprotective during myocardial ischemia and 
reperfusion through a NO-dependent mechanism. To 
investigate whether the ETA and ETB receptor antagonist, 
bosentan, is cardioprotective in atherosclerotic mice, 
buffer-perfused hearts from apolipoprotein E/LDL 
receptor double knockout and wild-type mice were 
subjected to global ischemia and reperfusion. Following 
reperfusion, the recovery of left ventricular function was 
equally impaired in wild-type and double knockout mice 
given vehicle. The ETA/ETB receptor antagonist bosentan 
improved recoveries in wild-type and in double knockout 
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mice. Similar effects were observed for the recovery of left 
ventricular end-diastolic pressure, developed pressure and 
dP/dt. Bosentan improved the recovery of coronary flow in 
both double knockout and wild-type mice. Recovery of 
coronary flow was significantly higher in the double 
knockout mice given bosentan than in the wild-type group. 
ET-1 impaired recovery of coronary flow in both wild-type 
and double knockout mice though this effect was more 
pronounced in the double knockout mice. Coronary 
outflow of NO during reperfusion was enhanced in both 
double knockout and wild-type mice following bosentan 
administration. Therefore, the ETA/ETB receptor 
antagonist bosentan may protect the atherosclerotic mouse 
heart from ischemia-reperfusion injury. The observation 
that endothelin receptor blockade and stimulation have a 
greater effect on coronary flow in atherosclerotic hearts 
indicates an increased activation of the endothelin system 
in atherosclerotic coronary arteries (242).  
In our laboratory we have compared the effects of 
antagonists for endothelin ETA and ETB receptors on the 
action of ischemia-reperfusion on endothelial and 
myocardial function. The study we carried out in 
anesthetized goats, in which 30 min of partial or total 
occlusion followed by 60 min of reperfusion of the left 
circumflex coronary artery was induced in animals treated 
with intracoronary administration of saline (vehicle), BQ-
123 (endothelin ETA receptors antagonist) or BQ-788 
(endothelin ETB receptors antagonist). During reperfusion 
after partial occlusion, coronary vascular conductance and 
left ventricle contractility were decreased after saline or 
BQ-788, and they normalized after BQ-123. In these three 
groups of animals, the coronary effects of Ach and sodium 
nitroprusside during reperfusion were as under control. 
During reperfusion after total occlusion, coronary vascular 
conductance and left ventricle function were decreased 
after saline, and they normalized after BQ-123 or BQ-788 
treatment. In these three groups of animals, the coronary 
effects of Ach but not those of sodium nitroprusside during 
reperfusion were decreased after saline, and they reversed 
after BQ-123 or BQ-788 treatment. Therefore, selective 
antagonists of endothelin ETB and ETA receptors may 
produce similar protection of coronary vasculature and 
myocardium against reperfusion after severe ischemia. 
Selective antagonists of endothelin ETB receptors, 
contrarily to those of endothelin ETA receptors may be 
ineffective to protect coronary vasculature and 
myocardium against reperfusion after mild ischemia. 
Probably it may be more beneficial the use of antagonists 
for both subtypes of endothelin receptors (243). In addition 
of antagonists for ETA receptors, the use of antagonists for 
ETB receptors is supported by studies performed in pig 
coronary arteries (202) in which it seems to be that 
ischemia-reperfusion increases the coronary 
vasoconstriction in response to ET-1 probably due to 
impairment of endothelin ETB receptor-induced release of 
NO and prostacyclin, to augmentation of the contractile 
response to activation of endothelin ETB receptors, and to 
increased release of vasoconstrictor prostanoids.  
Left ventricular hemodynamic variables were measured 
in the Langendorff-perfused model after 40- and 20-
minute regional or global ischemia, followed by 30-minute 
reperfusion. Wild-type and ETB-deficient rats were 
compared. Left ventricular dysfunction was more 
prominent in ETB-deficient rats, particularly after regional 
ischemia. Infarct size was smaller in wild-type than ETB-
deficient rats after 40 minutes of regional ischemia-
reperfusion. Although the recovery of left ventricular 
function was poorer after 40-minute ischemia-reperfusion, 
end-diastolic pressure in ETB-deficient rats was higher 
after 20 than after 40 minutes of regional ischemia-
reperfusion. It is concluded that ETB receptors exert 
cytoprotective effects in the rat heart, mainly after regional 
ischemia-reperfusion. Longer periods of ischemia suppress 
the recovery of left ventricular function after reperfusion, 
but the role of ETB receptors may be more important 
during the early phases (244).  
In rabbits subjected to 1 h of coronary artery occlusion 
followed by 3 h of reperfusion, left ventricle unloading 
was initiated 15 min prior to reperfusion and was 
maintained during reperfusion. Animals were treated with 
the ETA receptor antagonist BQ123. In parallel, isolated 
rabbit cardiomyocytes subjected to simulated ischemia-
reperfusion with or without ET-1 or BQ123, intracellular 
calcium and cell death were assessed with flow cytometry. 
From the results of this study, the authors suggest that 
components of reperfusion injury involve ET-1 release 
which stimulates calcium overload and apoptosis. 
Intravenous ETA receptor blockade prior to reperfusion 
may be a protective adjunct to reperfusion therapy in acute 
myocardial infarction patients. Thus, endogenous ET-1 
released during acute myocardial infarction might mediate 
ischemia-reperfusion injury by stimulating increased 
intracellular calcium concentration, and apoptosis (245).  
In patients with type 2 diabetes and coronary artery 
disease it has been observed that both selective ETA and 
dual ETA/ETB receptor antagonists improve endothelium-
dependent vasodilatation. ETB receptor blockade increases 
basal blood flow but does not additionally improve 
endothelium-dependent vasodilatation (246). Safety and 
feasibility of selective ETA receptor blockade in ST-
elevation acute coronary syndrome (STE-ACS) within a 
larger randomized trial was assessed in patients. Patients 
with posterior-wall STE-ACS were randomly assigned to 
receive intravenous BQ-123 or placebo over 60 min, 
starting immediately prior to primary percutaneous 
coronary intervention. Twenty-four hour Holter recordings 
were performed during hospitalization for STE-ACS and 
after 6–8 weeks. The predefined primary endpoint was the 
documentation of ventricular tachycardia and/or late 
potentials at follow-up. Based on the analysis of long-term 
ECG data, short-term administration of BQ-123 after AMI 
was safe (247).  
The studies shown before support the idea that ET-1 
could play a relevant role in the adverse effects of 
ischemia-reperfusion on the myocardium, including 
coronary vasculature. These adverse effects of ET-1 may 
Coronary ischemia-reperfusion: role of nitric oxide and endothelin-1. A Review 
@Real Academia Nacional de Farmacia. Spain 39 
be mediated by both endothelin ETA and ETB receptors; 
endothelin ETB receptors situated in the endothelium may 
reduce their function probably due to endothelium damage, 
whereas those situated in smooth muscle cells of coronary 
arteries acquires a high role and thus contributing, together 
with endothelin ETA receptors, to the adverse coronary 
effects of ET-1. Thus, the treatment with blockers of both 
endothelin ETA and ETB receptors may protect the 
myocardium and coronary vasculature against the adverse 
effects of ischemia-reperfusion, and in consequence it may 
reduce reperfusion injury.  
H) Urocortin. This substance is a 40 amino-acid 
peptide which has a high degree of structural homology 
with the peptide corticotrophin-releasing factor (CRF), and 
has marked cardiovascular effects. In the heart, exogenous 
urocortin produces coronary vasodilation (248). Also, it 
has been demonstrated that urocortin production may be 
increased in cardiac cells exposed to ischemia and that 
exogenous urocortin may protect myocardium during 
coronary ischemia (249), and that urocortin reduces the 
infarct area in the ischemic and reperfused rat heart (250). 
Several mechanisms may be involved in this protective 
effect of urocortin in the myocardial cells (251). To 
explore the action of urocortin on the adverse effects of 
ischemia-reperfusion on coronary vasculature, hearts from 
rats were perfused at constant flow and then exposed to 15 
mins ischemia followed by 15 mins reperfusion. In one 
series of experiments, we found that the coronary 
relaxation to urocortin was reduced after ischemia-
reperfusion. Treatment with a low threshold concentration 
of urocortin, administered before ischemia and during 
reperfusion, improved the coronary relaxation to Ach after 
ischemia-reperfusion. Therefore, this condition impairs the 
coronary vasodilation to urocortin and produces 
endothelial dysfunction, and this endothelial dysfunction 
may be improved by urocortin (252).  
In other series of experiments (253), we observed that 
the urocortin-induced improvement of the coronary 
relaxation to Ach after ischemia-reperfusion was not 
modified by treatment with tetraethylammonium, blocker 
of Ca2+ dependent-potassium channels; glibenclamide, 
blocker of K (ATP) channels; L-NAME, blocker of NO 
synthesis; or meclofenamate, blocker of cyclooxygenase, 
but it was abolished by chelerythrine, blocker of protein 
kinase C Thus, it is suggested that urocortin may protect 
coronary endothelial function during ischemia-reperfusion 
by activation of protein kinase C. Therefore, urocortin may 
act as an endogenous protective factor of the heart during 
ischemia. These protective effects of urocortin may act on 
the endothelial function (252) as well as on the myocardial 
function (249, 250) during ischemia-reperfusion. Urocortin 
may activate ATP-sensitive and Ca2+-sensitive potassium 
channels in cardiac myocytes and in vascular smooth 
muscle cells, respectively. However, we found that neither 
glibenclamide nor TEA modified the urocortin-induced 
improvement of the coronary endothelial function, 
suggesting that these channels do not seem to be involved 
in the protective effect of urocortin on endothelial cells 
during ischemia-reperfusion. Brar et al also suggest that 
the protective effect of urocortin on the endothelial cells 
during ischemia-reperfusion may be mediated by 
activation of protein kinase C, as an inhibitor of this 
enzyme, chelerythrine, abolished the improvement of 
endothelial function by urocortin (249). Gordon et al. 
(254) also found that the protection by urocortin against 
ischemia-reperfusion in adult rat cardiomyocytes was 
attenuated by chelerythrine. Also, our results partly agree 
with those of Lawrence et al. (255), who showed 
involvement of protein kinase C epsilon in the prevention 
of mitochondrial damage during ischemia-reperfusion. 
However, in the studies of Gordon et al. (254) and 
Lawrence et al. (255), KATP channels were also involved, 
a phenomenon that was not observed in our study. It may 
be supposed that urocortin action may share some 
mechanisms, but not others, in endothelial and myocardial 
cells. In conclusion, our results suggest that relatively low 
concentrations of urocortin may protect endothelial 
function in the coronary circulation against deleterious 
effects of ischemia-reperfusion through activation of 
protein kinase C. Urocortin might act as an endogenous 
protective factor in the heart during coronary ischemia-
reperfusion, and identification of its protective 
mechanisms on endothelial function may help to prevent 
the coronary vascular dysregulation that occurs after heart 
ischemia (252, 253). With respect to this, it is remarkable 
that a recent study in humans (256) provided the first 
evidence that human urocortin prevents the development 
of atherosclerosis by suppressing endothelial cell 
inflammatory response and proliferation, macrophage 
foam cell formation, and vascular smooth muscle cell 
migration and proliferation. Thus, human urocortin might 
serve as a novel therapeutic agent for atherosclerotic 
cardiovascular diseases (256).  
5. CONCLUSIONS 
Acute coronary syndromes (e. g., acute myocardial 
infarction (AMI) ) are the most lethal of cardiovascular 
diseases, but the mortality rates of these syndromes are 
going down in developed countries as a result of better 
prevention and treatment. The most effective treatment of 
AMI is timely (early) reperfusion of the myocardial 
ischemic zone. However, not all it is favorable with 
myocardial reperfusion as this procedure may also damage 
myocardium, which is known as “reperfusion injury”.  
The present Review pays particular attention to the 
coronary circulation and to the role of NO and ET-1 in the 
regulation of this circulation under normal conditions and 
after ischemia-reperfusion. Also, it is considered 
therapeutical strategies for ischemia-reperfusion injury, 
with special mention to antagonists for endothelin 
receptors. The coronary circulation plays a crucial role in 
pathophysiology of ischemia-reperfusion and reperfusion 
injury, after all it is the cause and victim of this condition. 
Ischemia-reperfusion damages not only cardiomyocytes, 
but also coronary vasculature. The damage to this 
vasculature may vary from functional impairment of 
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endothelium to severe structural alterations of the 
vasculature, and finally to vascular thrombosis and the no-
reflow phenomenon, which may underly reperfusion 
injury. The endothelium plays a relevant role in the 
regulation of the coronary circulation, and it could exist a 
functional interaction between NO and ET-1 in the 
coronary artery wall, with predominance of NO over ET-1 
and also with a relevant role of NO in modulation of 
coronary effects of ET-1under normal conditions. The 
endothelium seems to be highly sensitive to ischemia, and 
after ischemia-reperfusion the endothelial function and the 
interaction between NO and ET-1are altered, and now ET-
1 predominates over NO and the modulator role of NO in 
the effects of ET-1 is decreased. These features lead to 
decreased endothelium-dependent coronary vasodilatation, 
particularly that mediated by NO, and also to increased 
coronary vasoconstrictor response to ET-1. After 
ischemia-reperfusion, the production of ET-1 seems to be 
augmented, and the equilibrium between endothelin 
receptors may be altered with an increased role of the 
smooth muscle cells ETA and ETB receptors in the 
augmented coronary vasoconstriction to ET-1. It is 
probable that ischemia-reperfusion by damaging the 
endothelium it decreases the NO-mediated vasodilation of 
coronary vessels, and at the same time it augments the 
production of ET-1 and its coronary vasoconstrictors 
effects. This damage of the endothelium and the 
augmented presence of ET-1 and of its coronary effects, 
would contribute to produce vascular dysfunction, vascular 
damage, vascular thrombosis and the non-reflow 
phenomenon, thus contributing to reperfusion injury. From 
these considerations, it can be suggested that ET-1 plays a 
significant role in pathophysiology of coronary ischemia-
reperfusion and of reperfusion injury, and therefore it is 
reasonable to expect that the use of antagonists for 
endothelin ETA and ETB receptors could be beneficial for 
protecting the heart against this condition.  
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